Biotechnology News and Information. Includes Arizona Biotechnology, Arizona Biotech news, genomics, biotech companies, genetic engineering, biotech research, biology and biological technology news and information.

BioTech News at Arizona Biotech

Biotech News <<< Mailing List

Biotechnology News <<< Discussion Forums

This site is a member of WebRing.
To browse visit Here.

Thursday, December 29, 2005

EMO Biomedicine of Taipei announces intent to form cell therapy joint venture with Chromos Molecular Systems of Canada to treat chronic Hepatitis B

EMO Biomedicine of Taipei announces intent to form cell therapy joint venture with Chromos Molecular Systems of Canada to treat chronic Hepatitis B

(Press release, Biotechnology & Pharmaceutical Industries Program Office (BPIPO) and EMO Biomedicine Corporation)

23 December, 2005
With the strong guidance and assistance of the BPIPO (Biotechnology & Pharmaceutical Industries Program Office, Ministry of Economic Affairs, Taiwan), and lead-in from MDS Capital of Canada, Danshuei Jen, Taipei, Taiwan-based EMO Biomedicine Corporation announced today that a Letter of Understanding to form a joint venture in Taiwan had been signed with Chromos Molecular Systems, Inc, a cell-engineering and development company based in Burnaby, British Columbia, Canada.

"We have an exciting opportunity to efficiently launch a clinical trial with an aim to cure chronic hepatitis B," said Shing-Mou Lee, President of EMO Biomedicine. "This chronic disease is endemic throughout Asia, and current treatments do not eliminate the progressive liver damage that can lead to hepatocellular carcinoma, the number one cause of death in men over 40 in Taiwan."

The Chromos REM technology is a proprietary method for the isolation and expansion of antigen-specific T-cells in order to enhance the body's natural ability to fight disease. The REM method selects the rare T cells that are capable of eliminating disease and expands these cells to clinically relevant numbers that allow the body to fight the disease effectively.

"We are extremely pleased to announce this agreement with EMO," said Alistair Duncan, President and CEO of Chromos. "The chronic hepatitis B product and the REM program are poised for immediate technology transfer and clinical testing can begin in the near term to address this long-term healthcare problem in the nation of Taiwan as well as the rest of Asia."

Under terms of a definitive agreement outlined in the letter of understanding, Chromos would provide the joint venture an exclusive license to use REM technology as a platform to develop and commercialize cell therapies for treatment of infectious disease and cancer in Taiwan and an option to expand its license to other parts of Asia. The joint venture will focus initially on obtaining product efficacy data by performing clinical trials to treat chronic Hepatitis B. Chromos will provide the existing clinical design and protocol, critical reagents, documentation, and on-site technology transfer for the manufacture of anti-Hepatitis B cell therapy product in Taiwan. EMO will provide the GTP manufacturing facility, personnel, clinical, quality, and regulatory oversight, and local and regional relationships and partnerships to manage the joint venture operations. Completing the transaction depends on securing adequate financing for the joint venture and signing definitive agreements.

"We look forward to working with our healthcare, university, government, and financial communities in Taiwan and other nations in Asia," said Lee. "Together, we can establish an innovative and exciting new company that seeks to address a substantial unmet medical need for patients in Asia who are suffering from this debilitating and eventually deadly disease"

About chronic Hepatitis B
HBV is a virus that infects liver cells and results in significant morbidity and mortality. The Hepatitis Foundation International estimates that more than 2 billion people worldwide have been exposed HBV and, of those, over 350.0 million people are chronically infected. While many HBV carriers show no outward signs of the disease, symptoms can include jaundice, fatigue, abdominal pain, loss of appetite, intermittent nausea and vomiting. In addition, approximately 25.0% to 30.0% of patients experience symptomatic disease such as cirrhosis (scarring of the liver), liver cancer and liver failure. The HBV vaccine is effective and generates more than US$1Billion in annual sales, however, current treatments and therapies for those already infected do not cure chronic HBV.

About EMO
EMO Biomedicine Corporation was founded in 2004 by Shing-Mou Lee, a cell therapy entrepreneur and medical technologist with former roles as VP of research at Alarvita BioLife and many years of senior research at the Development Center for Biotechnology in Taipei. EMO's new class 10,000 GTP pilot manufacturing facility is designed to manufacture product for Phase I and II clinical trials. EMO also provides cell-based assay services to quality healthcare, pharmaceutical, and biotechnology clients in Taiwan, Japan, and China.

About Chromos
Chromos employs proprietary technology to develop, manufacture and commercialize innovative biological therapies for debilitating diseases. Chromos has exclusive worldwide rights to two platform technologies, the ACE System (Artificial Chromosome Expression System) and REM (Rapid Expansion Method) technology. In the near term, Chromos will focus on continued commercialization of the ACE System for engineering cell lines for biopharmaceutical manufacture. To date Chromos has entered into corporate partnerships with partners including Pfizer Inc., Centocor, Inc., BD (Becton, Dickinson and Company) and Cambridge Antibody Technology. In addition, the Company has strategic alliances with AppTec Laboratory Services, Inc., a leading biopharmaceutical contract manufacturer and with SAFC Biosciences, a member of the Sigma-Aldrich Group providing cell culture media development services to biopharmaceutical customers.

Certain of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

For further information:
Shing-Mou Lee,
President, EMO Biomedicine Corp.
Tel: 886 2 28096390
Email: smlee@emobio.com
Website: www.emobio.com

Joseph Zendegui, Ph.D.
Vice President, Corporate Development
Chromos Molecular Systems, Inc.
Tel: 604-415-7128
Email: jzendegui@chromos.com
Website: www.chromos.com

http://groups.yahoo.com/group/biotech-news/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Wednesday, December 28, 2005

[ biotech news ] The Biotechnology Venture Capital Best Practices Conference - the World's Top VC

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

The Biotechnology Venture Capital Best Practices Conference - the
World's Top VCS On Valuations, Exit Strategies and Investment
Practices
Aspatore, Inc., Nov 2005

Description

The Biotechnology Venture Capital Best Practices Conference features
eight speeches totaling more than three hours of authoritative,
insider's perspectives on the best practices of the world's top
biotechnology venture capital firms. Featuring managing and venture
partners from some of the nation's top companies, this conference
provides a broad yet comaprehensive overview of the biotechnology
venture capital world, presenting to attendees superior venture
capital strategies. Each speaker shares their insight for thriving
business practices and industry expertise in a format similar to a
radio address, with graphics displayed in the background. Simply
insert the CD-ROM into your computer, sit back, and watch and learn
from the top professionals in the field as they discuss their
specific strategies for valuating companies, attaining exit
strategies, and ensuring success. The breadth of perspectives
presented enable attendees to get inside some of the great minds of
the biotechnology venture capital world without leaving the office.
The conference has been produced on CD-ROM and can be viewed in
PowerPoint by any PC-based computer.

http://www.researchandmarkets.com/reports/c29415/

In this CD-ROM you will learn:

- How to make successful investments in Biotechnology VC.
- The biggest factors in establishing a Biotechnology VC valuation.
- How valuations change with different funding rounds.
- The Top 5 things an entrepreneur can do to increase their chances
for a higher valuation
- The best time to pursue an exit strategy in Biotech VC.

http://www.arizonabiotech.com/
http://www.quotescentral.com/index.php
http://groups.yahoo.com/group/biotech-news/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] BIO to Host Japan Trade Mission at Pacific Rim Summit on Industrial Biotechnolog

BIO to Host Japan Trade Mission at Pacific Rim Summit on Industrial
Biotechnology

WASHINGTON, Dec. 28 -- The Biotechnology Industry
Organization (BIO), the U.S. Embassy in Tokyo, and the state of
Hawaii will host a Japanese Bio Mission at the Pacific Rim Summit on
Industrial Biotechnology and Bioenergy in Honolulu Jan. 11-13,
2006. BIO is sponsoring the conference in conjunction with the
state of Hawaii, the University of Hawaii, the Hawaii Life Sciences
Council (HLSC), Enterprise Honolulu, and the Oceanic Institute.

"The purpose of the conference is to highlight the emerging
field of industrial biotechnology, which is being used to convert
agricultural wastes to renewable energy and to make many types of
manufacturing processes more environmentally sustainable," said
Brent Erickson, executive vice president of BIO's Industrial &
Environmental Section. "BIO sees regional biobased economies
emerging in various states of complexity and development. The trend
is clear that industrial biotech is growing in importance in the
Pacific Rim countries."
The trade mission will be made up of 13 individuals from
Japanese biotech and energy companies, universities, newspapers, and
embassy officials, all seeking opportunities to do business with
U.S. producers of biobased goods and materials. Japan and other
Pacific Rim nations are increasingly looking for sustainable sources
of energy, and cleaner, more efficient methods of industrial
production, including new ways to make pharmaceuticals and other
chemicals. Biotech applications that can enable industrial
processes to use agricultural instead of petrochemical feedstocks
are growing in importance in the Pacific Rim countries.
Participants in the Japanese BIO Mission include the Committee
for Energy Policy Promotion, RIKEN Plant Science Center, Bio Matrix
Research Inc., Kona Stones Inc., and Osaka University.

BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the United States and 31 other nations. BIO members are
involved in the research and development of healthcare,
agricultural, industrial and environmental biotechnology products.

SOURCE Biotechnology Industry Organization
Web Site: www.bio.org

http://www.arizonabiotech.com/
http://www.quotescentral.com/index.php
http://groups.yahoo.com/group/biotech-news/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

China, Cuba sign biotech pact .:. NewKerala - India's Top Online Newspaper

China, Cuba sign biotech pact .:. NewKerala - India's Top Online Newspaper

China, Cuba sign biotech pact
Beijing : Giving a boost to growing ties, China and Cuba have signed an agreement to develop projects in biotechnology, Cuban news agency Prensa Latina reported.

The accord, spread over the next three to five years, sets up the bases for continued biotech projects, promotes new ones and opens the way for further exploring collaboration in health.

Visiting Cuban minister Ricardo Cabrisas signed the pact with Zhang Xiaoqiang, China´s vice chairman of the State Development and Reform Commission.

Love Quotes Chicken Recipes

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

As biotech drug prices rise, U.S. hunts for solution

As biotech drug prices rise, U.S. hunts for solution

As biotech drug prices rise, U.S. hunts for solution
Wednesday, December 28, 2005

By Geeta Anand, The Wall Street Journal

The most innovative part of the drug industry is generating its most explosive prices.

Spending on specialty pharmaceuticals -- biotechnology drugs and other expensive medicines prescribed by medical specialists -- is growing twice as fast as traditional prescription drugs, according to Medco Health Solutions Inc., one of the largest pharmacy benefits managers. Insurers project it will grow by between 20 percent and 50 percent annually. It reached $42 billion in 2004 and will rise to almost $69 billion next year, when spending on specialty pharmaceuticals is projected to make up 25 percent of the nation's pharmacy bill, according to Health Strategies Group, a New Jersey consulting firm.

chicken recipes Famous Quotes

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

The Impact of Emerging Technologies: Best in Biotech for 2005

Best in Biotech for 2005

The Impact of Emerging Technologies: Best in Biotech for 2005

Stem cell quandaries, a map of human genetic variability, a lengthy debate on lifespan extension -- this year in biotech was one to remember.

Chicken Recipes Funny Quotes

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Friday, December 23, 2005

Merry Christmas Everyone - Christmas Recipes and Christmas Sites

Christmas Recipes and Christmas Sites

Christmas Recipes and Christmas Sites

Christmas Weblog

Christmas Recipes

Christmas Recipes Page

Christmas Recipes

Christmas Recipes Search

Recipes - World Famous Recipes

Christmas Recipes Category

Recipes � Christmas Recipes - World Famous Recipes

Other Christmas Sites

Christmas Stockings

Christmas Quotes

A Christmas Carol by Charles Dickens

Christmas Quotes

Christmas Carol Lyrics

The Life and Adventures of Santa Claus

Christmas Tree Clipart

Christmas

Christmas Gifts Shopping Online

Christmas Songs Lyrics

Christmas Sites Search

Christmas Jokes

Christmas Music

Christmas Recipes and Christmas Sites

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Tuesday, December 20, 2005

[ biotech news ] Mendel Biotechnology Awarded SBIR Phase IIB Grant for Continued Research

Mendel Biotechnology Awarded SBIR Phase IIB Grant for Continued
Research on Disease Resistance

HAYWARD, California -- 15 December 2005 -- Mendel Biotechnology,
Inc., a privately held biotechnology company, announced today that
it was granted a Phase IIB Small Business Innovation Research (SBIR)
grant from the National Science Foundation. The SBIR phase IIB grant
provides two years of supplemental funding for a Phase II grant
awarded to Mendel Biotechnology, Inc. for development of crops with
improved disease resistance, based on matching funds from a third
party investor. Protection of crops against fungal pathogens is one
of the most significant unmet needs in agriculture. Over $600
million is spent each year in the United States to protect plants
against fungal pathogens. Nonetheless, annual losses to fungal
pathogens are approximately $900 million in North America for
soybean alone, with total crop losses of approximately $5 billion.
The grant will fund research that aims to enhance a plant's natural
ability to resist pathogen infection, thereby reducing or
eliminating the need for fungicides.

T. Lynne Reuber, Ph.D., Director of Research, will serve as the
Principal Investigator of the grant.

Founded in 1997, Mendel Biotechnology, Inc. was a pioneer in the
application of functional genomics to the study of plant genes.
Mendel's initial mission, now largely complete, was to discover and
characterize the function of plant transcription factor genes as the
basis for creating novel products for agriculture. Mendel is now
commercializing transcription factor technologies in the
agricultural biotechnology and chemistry sectors. Products
incorporating Mendel technologies are being developed for large
acreage row crops, and for the forestry, ornamental and
horticultural markets. Mendel has partnerships with leading
agriculture companies, including Monsanto, the world's leader in
commercializing transgenic crops.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] The Maize Genetics and Genomics Database

The Maize Genetics and Genomics Database. the Community Resource for
Access to Diverse Maize Data

Authors

Lawrence, Carolyn
Seigfried, Trent
Brendel, Volker - IOWA STATE UNIVERSITY

Submitted to: Plant Physiology
Publication Acceptance Date: January 27, 2005
Publication Date: May 2, 2005
Publisher's URL:
http://www.plantphysiol.org/cgi/content/abstract/138/1/55
Citation: Lawrence, C., Seigfried, T.E., Brendel, V. 2005. The Maize
Genetics And Genomics Database. The Community Resource For Access To
Diverse Maize Data. Plant Physiology. 138(1):55-58.

Interpretive Summary: Maize (referred to commonly as corn or by its
botanical name Zea mays L. spp. mays) is an important crop. Not only
is it a source of food for both people and livestock the world over,
it also is an important component of many items where its content is
less apparent. Maize is used in the manufacture of diverse
commodities including glue, paint, insecticides, toothpaste, rubber
tires, rayon, molded plastics, and the list goes on. Maize also is
the nation¿s major source of ethanol, a fuel that is more
environmentally friendly than gasoline and that may turn out to be a
more economical fuel alternative in the long run. Access to data
describing the biology of maize is of interest to researchers the
world over. The depth and breadth of biological data related to
maize is ever increasing, and researchers need to be able to search
across data and to find information. This functionality coupled with
worldwide accessibility could only be realized by storing the data
in a relational database and making that information available
through an online Web interface. By creating logical connections
between, for example, how a plant looks and the genetic sequences
responsible for causing that phenotype, researchers can use data
created in the past as a springboard for future experiments. This
manuscript describes technical, curatorial, and usage aspects of the
Maize Genetics and Genomics Database (MaizeGDB) project and
demonstrates how the database can be used to solve problems by way
of a few example usage cases. This information described in this
manuscript will aid scientists and stakeholders interested in maize
genetics and genomics (including those involved in breeding and crop
improvement, as well as the public at large) to find information
describing traits, phenotypes, genotypes, and other related data for
maize.
Technical Abstract: The Maize Genetics and Genomics Database
(MaizeGDB) serves the maize (Zea mays) research community by making
a wealth of genetics and genomics data available through an
intuitive Web-based interface. The goals of the MaizeGDB project are
three-fold: to provide a central repository for public maize
information; to present the data through the MaizeGDB Web site in a
way that recapitulates biological relationships; and to provide an
array of computational tools that address biological questions in an
easy-to-use manner at the site. In addition to these primary tasks,
MaizeGDB team members also serve the community of maize geneticists
by lending technical support for community activities, including the
annual Maize Genetics Conference and various workshops, teaching
researchers to use both the MaizeGDB Web site and Community Curation
Tools, and engaging in collaboration with individual research groups
to make their unique data types available through MaizeGDB.

http://www.ars.usda.gov/research/publications/publications.htm?
seq_no_115=183344

http://www.maizegdb.org/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

EFY Times

EFY Times

California Urged To Take Nanotechnology Lead

(Tuesday, December 20, 2005 11:03:59 AM)

California asked to make investments to lead the nanotechnology revolution.

Monday, December 19, 2005: To be at the centre of the estimated one trillion dollar nanotechnology industry, California has been urged to make immediate investments in education and infrastructure. But that's only the beginning. The nascent sector promises countless other breakthroughs from toothpaste to spacecraft. The state will be promoted as the world leader in nanotech by hosting events.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
High Tech
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Cancer Genomics - NIH Cancer Genome Atlas

NIH Launches Comprehensive Effort to Explore Cancer Genomics: The
Cancer Genome Atlas Begins With Three-Year, $100 Million Pilot

Cancer Treatment
http://www.imhcaz.com/

The National Cancer Institute (NCI) and the National Human Genome
Research Institute (NHGRI), both part of the National Institutes of
Health (NIH), today launched a comprehensive effort to accelerate
our understanding of the molecular basis of cancer through the
application of genome analysis technologies, especially large-scale
genome sequencing. The overall effort, called The Cancer Genome
Atlas (TCGA), will begin with a pilot project to determine the
feasibility of a full-scale effort to systematically explore the
universe of genomic changes involved in all types of human cancer.

"Now is the time to move forward with this pioneering initiative.
Thanks to the tools and technologies developed by the Human Genome
Project and recent advances in using genetic information to improve
cancer diagnosis and treatment, it is now possible to envision a
systematic effort to map the changes in the human genetic blueprint
associated with all known forms of cancer," said NIH Director Elias
A. Zerhouni, M.D. "This atlas of genomic changes will provide new
insights into the biological basis of cancer, which in turn will
lead to new tests to detect cancer in its early, most treatable
stages; new therapies to target cancer at its most vulnerable
points; and, ultimately, new strategies to prevent cancer."

NCI and NHGRI announced today at a news conference in Washington,
D.C., that they have each committed $50 million over three years to
the TCGA Pilot Project. The project will develop and test the
complex science and technology framework needed to systematically
identify and characterize the genetic mutations and other genomic
changes associated with cancer. The pilot will involve a few types
of cancer that will be chosen for their value in helping to
determine the feasibility of a possible larger-scale project. The
process for determining the types of cancers to be studied is
currently underway.

Cancer is now understood to include more than 200 different
diseases. In all forms of cancer, genomic changes -- often specific
to a particular type or stage of cancer -- cause disruptions within
cellular pathways that result in uncontrolled cell growth. TCGA will
delve more deeply into the genetic origins leading to this complex
set of diseases, and, in doing so, will create new discoveries and
tools that will provide the basis for a new generation of cancer
therapies, diagnostics, and preventive strategies.

"The goal of studying the human genome has always been to improve
human health. The Cancer Genome Atlas Pilot Project represents
another bold step in that direction," said National Human Genome
Research Institute Director Francis S. Collins, M.D., Ph.D. "Such an
ambitious venture requires significant planning. Given the genetic
complexity of cancer, we are certain to face many daunting
challenges in this pilot. But by pulling together some of the best
minds in the cancer and genomics research communities, I am
confident that the pilot will succeed, and we will go on to develop
an atlas that will accelerate cancer research in ways we cannot even
imagine today."

NCI Deputy Director Anna D. Barker, Ph.D., said, "The Cancer Genome
Atlas Pilot Project is a revolutionary step in cancer medicine that
leverages advances in cancer biology, genomics technologies,
biorepositories, and bioinformatics for the ultimate benefit of
cancer patients. Key challenges for the TCGA Pilot Project include
not only addressing cancer's complexity, but also developing the
technologies to advance the science of cancer genetics. A better
understanding of cancer genetics is part of the overall effort to
eliminate the suffering and death due to cancer."

Data and technologies produced by other genomic projects have
provided the tools necessary to produce new insights into how and
why genetic changes cause cancer. The Human Genome Project, an
international effort led in the United States by NHGRI and the
Department of Energy, was completed in April 2003 and provided a
reference DNA sequence of the human genome. The Human Genome Project
also helped to advance sequencing technologies and paved the way for
other genome-based research tools, including a comprehensive map of
human genetic variation, or haplotypes, recently produced by the
International HapMap Consortium.

Genetic mutations linked to breast cancer, colon cancer, melanoma,
and other cancers already have led to diagnostic tests that can
point to the most effective intervention. Recent discoveries in
cancer genomics have helped to identify several treatments that work
by targeting cancer cells with a specific genetic change, such as
Gleevec®, a drug for chronic myeloid leukemia and gastrointestinal
stromal tumors, and Herceptin®, a drug for one form of breast
cancer. These successful developments support further examination of
the molecular origins of cancer to more quickly develop new tools to
diagnose, treat, and prevent cancer.

In the TCGA Pilot Project, a Human Cancer Biospecimen Core Resource
will support the collection, processing, and distribution of
cancerous and healthy, control tissue samples to Cancer Genome
Characterization Centers and Genome Sequencing Centers. The genes
and other genomic targets identified will be sequenced by the Cancer
Genome Sequencing Centers using high-throughput methods similar to
those employed in the Human Genome Project. The Cancer Genome Atlas
Pilot Project seeks to identify genetic mutations in the DNA code
that are specifically associated with the type of cancer being
sequenced. In addition, the Cancer Genome Characterization Centers
will work to identify other types of larger-scale genomic changes,
such as copy number changes and/or chromosomal translocations, that
contribute to cancer development and/or progression.

These data from TCGA Centers will be deposited in public databases
supported by NCI's cancer Biomedical Informatics Grid (caBIG) and
the National Library of Medicine's National Center for Biotechnology
Information. As in the Human Genome Project, TCGA data will be made
available to the worldwide research community. This data will
provide researchers and clinicians with an early glimpse of what is
hoped will evolve into an unprecedented, comprehensive "atlas" of
information describing the genomes of all cancers. This atlas will
enable researchers throughout the world to analyze and use the data
in their own research to develop new diagnostics and therapies for
different cancers.

Recognizing that not all technologies needed for high-throughput,
cost-effective analysis of the cancer genome are already in hand,
TCGA also will support new technology development. Some of these
methods will focus on improving current genomic analysis
technologies, while others will emphasize new approaches, such as
epigenomics. Epigenomics looks at how various small molecules, such
as methyl groups, when added or removed from DNA, can have profound
effects on gene function.

Each component of the TCGA Pilot Project will have clear milestones
and goals. Only if the pilot achieves its goals will the full-scale
project to develop a complete atlas of the cancer genome move
forward.

The Cancer Genome Characterization Centers, Genome Sequencing
Centers, and Biospecimen Core Resources will be selected in 2006.
Applications and proposals will be reviewed by experts in the field,
and awards will be based on merit and programmatic needs of The
Cancer Genome Atlas Pilot Project.

####

NCI and NHGRI are two of the 27 institutes and centers at NIH, an
agency of the U.S. Department of Health and Human Services.

For more details about The Cancer Genome Atlas, including Q&As, a
graphic, a glossary, a brief guide to genomics, and a media library
of available images, please go to http://cancergenome.nih.gov.

For more information about cancer and the National Cancer Institute,
please visit the NCI Web site at http://www.cancer.gov, or call
NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

Additional information about NHGRI can be found at its Web site,
http://www.genome.gov.

http://www.imhcaz.com/
http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.alternativecancertreatmentcenter.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Southeast Nebraska Cancer Center Receives Major Research Funding

Southeast Nebraska Cancer Center Receives Major Research Funding
Tuesday December 20, 9:30 am ET

LINCOLN, Neb., Dec. 20 The U.S. Congress directed $1.5 million in
cancer research funding to the Southeast Nebraska Cancer Center as
part of the Department of Defense appropriations for the current
fiscal year.

This critical new funding will allow doctors and researchers at
Lincoln- based Southeast Nebraska Cancer Center to develop new, more
effective treatments for cancer patients based on their molecular
profile. This funding is expected to be signed into law soon.

"This research will help us identify genomic sequence changes
associated with cancer in individual patients," said Dr. Mark
Carlson with the Southeast Nebraska Cancer Center.

"Our hope for the future is that your doctor can run a simple test
on a small tumor sample and use a quick genetic analysis to tailor
the best therapy for you as an individual," explains Dr.
Carlson. "It looks increasingly promising that this form of genetic
testing will improve development of cancer therapy and help more
people survive cancer."

Some call this personalized medicine. This Lincoln cancer center is
now part of a fundamentally different way to cure disease. Delving
more deeply into the genetic origins leading to this complex set of
diseases will help create new discoveries and tools for a new
generation of cancer prevention, diagnostic and therapy strategies.

"Cancer is a very complex disease that will kill over 560,000
Americans this year," explains Rep. Jeff Fortenberry, R-Neb. "This
research will link cancer research around the country and
potentially revolutionize the diagnosis, treatment and prevention of
cancer," Fortenberry said in announcing the research funding. Both
U.S. Senator Chuck Hagel and Sen. Ben Nelson worked closely with
Rep. Fortenberry to bring this research funding to Nebraska.

"We are pleased that Nebraska will help explore how physicians can
use this information to save lives. It is a great opportunity for
our local medical community to work together on new ideas in cancer
therapy. For the seriously ill, we will create access to the latest
research ideas in a hometown setting," Fortenberry adds.

The funding is part of an ongoing Department of Defense technology-
transfer initiative. This program is aimed at moving dual-use
discoveries and medical treatments more rapidly into society, so
both the military and the public benefit from government research.
In this case, the Southeast Nebraska Cancer Center will be part of
the U.S. Department of Defense's National Functional Genomics Center.

The Southeast Nebraska Cancer Center will use the funds to create a
local network to collect cancer tissue samples from patients and
follow these patients' progress through therapy. Information will be
merged into a massive nationwide database that will help physicians
make personalized cancer treatment decisions.

This large-scale effort combines government, academic and private-
sector resources. The program also uses a "systems biology" approach
that brings together advanced science in pharmaceuticals, molecular
biology, genetic screening, bio-informatics systems and other
technology.

"This program will be very meaningful in Nebraska," adds Tracy
Christianson, Director of Research, Southeast Nebraska Cancer
Center. "The latest figures indicate that more than 8,000 new cases
of invasive cancer will be diagnosed among our state's citizens.
Sadly, we will experience nearly 3,500 deaths, based on these
estimates. Cancer is the second-leading cause of death in Nebraska,
after heart disease. This research will help us make faster progress
in solving a critical health issue for our state and our country."

While great strides have been made in cancer research, says
Christianson, more must be done. "We can now study tens of thousands
of variations at a time, rather than focus on single genes. We can
open new frontiers in medical knowledge for new cures, faster, and
more effectively than ever before," she added.

The Southeast Nebraska Cancer Center is a unique participant in this
program, Christianson adds.

"The other participants are large medical research institutions
around the country," she explains. "Our center is the only local
physician's clinic in the program. We are the pioneer in launching
this diagnostic innovation into a local medical community. What we
learn will be the model nationally."

The Southeast Nebraska Cancer Center has an active clinical research
program, she says. This made it an ideal candidate to be the first
local community based center to participate in the program.

"Our main goal in doing clinical trials is to offer our patient's
the latest options in cancer treatment. Our clinical study program
matches very well with this effort to implement the latest
innovations in using genetics to diagnose the most effective
treatment alternatives."

---------------------------------------------------------------------
-----------
Source: Southeast Nebraska Cancer Center

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] U.S. Invests $9.5 Billion in R&D for Developing Nations

U.S. Invests $9.5 Billion in R&D for Developing Nations
Tuesday December 20, 3:15 pm ET
First Known Estimate of Public and Private Funding for Global Health
Research

http://www.arizonabiotech.com/

WASHINGTON, Dec. 20 Public and private sources in the U.S. spent
$9.5 billion in 2003 on research and development (R&D) to improve
health in developing nations, according to a new report from
Research!America.

The benchmark study, supported by a grant from The Ellison Medical
Foundation, is the first known estimate and analysis of the United
States' total investment in R&D for global health. It focuses on
U.S.-funded research that aims to improve health in developing
nations and measures Americans' attitudes toward that research.

"This analysis brings a long-overdue look at what our nation invests
in the health of the developing world," said The Honorable John
Edward Porter, Research!America board chair and former U.S.
Congressman. "We can no longer afford to view human health as solely
a domestic issue. For humanitarian, economic and national security
reasons, America needs strong, sustained investment in health and
medical research to address needs both within and beyond our
borders."

U.S. investment in global health research flows primarily from three
sectors:

* Pharmaceutical and biotech companies contributed the majority
of global
health R&D funding in 2003 -- about 58%, or $5.5 billion.
This amount
does not include donations of materials, facilities or
expertise for
global health needs.

* The U.S. government funded about 36%, or about $3.4 billion,
in 2003.

-- 87% of that -- $3 billion -- came from the National
Institutes of
Health;

-- The remaining 13% came from the U.S. Agency for
International
Development ($338 million), the Centers for Disease
Control and
Prevention ($24 million), the Department of Defense ($61
million)
and Department of State ($10 million).

* Private foundations contributed $505 million in 2003.

In comparison with the $9.5 billion 2003 global health R&D
investment, a recent Research!America report estimates that public
and private U.S. sources invested $109 billion in 2004 for all
health R&D, for domestic and global needs.

"Tracking U.S. investment in health research overall is challenging,
and particularly so when trying to parse out the portion directed at
solving health concerns in low- and middle-income countries," said
Research!America's Stacie Propst, PhD, who led the development of
both reports. "However, we believe this to be the most comprehensive
estimate to date of global health R&D spending by the United States."

Global Health R&D and Public Opinion

Research!America has tracked Americans' views on medical and health
research for more than a decade, and global health registers as a
strong priority. Nine in 10 Americans say they are concerned about
the health problems facing the world (2004, Harris Interactive for
Research!America).

"Large majorities of Americans support the United States investing
considerably more to improve health and quality of life worldwide as
well as at home," said Mary Woolley, president and CEO of Research!
America. "They also strongly support eliminating health disparities
in order to speed cure, treatment and prevention of disease,
disability and injury for people everywhere."

A 2004 Research!America survey on global health showed:

* 93% of Americans say the U.S. should spend more on global
health
research.

* Concerns about global health problems include contagious
diseases
reaching the U.S. (93%) and health problems elsewhere causing
economic
(82%) or national security (77%) problems here.

* Americans say the U.S. should be involved in improving health
around the
world because we are the world's leader in scientific
expertise and
medical research (78%). Other reasons include preventing
future health
crises and disease outbreaks (78%) and protecting Americans'
health
(77%).

About the Report
The global health R&D report builds on Research!America's estimates
of the total U.S. investment in health research. Data in those
reports shows U.S. public and private sources spent $1.55 trillion
overall on health in 2002, with $92 billion of that on research --
or 6% of the total. For 2004, the U.S. total health expenditure was
$1.8 trillion, and Research!America estimates that $109 billion went
toward research.

Research!America is the nation's largest not-for-profit public
education and advocacy alliance working to make medical and health
research-including research to prevent disease, disability and
injury and to promote health-a much higher national priority. Its
500 member organizations represent the voices of more than 100
million Americans. To read the global health R&D report, visit
www.researchamerica.org.

---------------------------------------------------------------------
-----------
Source: Research!America

http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Monday, December 19, 2005

[ biotech news ] Pharmion Corporation and GPC Biotech Announce Partnering Agreement for Satraplat

Pharmion Corporation and GPC Biotech Announce Partnering Agreement
for Satraplatin

* Pharmion Obtains Commercial Rights for Satraplatin in Europe,
Turkey, the Middle East, Australia and New Zealand; GPC Biotech
Retains Rights in North America and all other Territories
* Pharmion to make an upfront payment of $37.1 million to GPC
Biotech; GPC Biotech may receive up to $270 million in total based
upon the achievement of regulatory and sales milestones
* Target Enrollment Achieved in Pivotal Phase 3 Study for Second-
Line Chemotherapy in Hormone-Refractory Prostate Cancer; Pharmion
Expects to Submit for European Marketing Authorization in 2007
pending concurrence with the EMEA

BOULDER, Colo., MARTINSRIED/MUNICH, Germany, WALTHAM, Mass. and
PRINCETON, N.J., Dec. 20 -- Pharmion Corporation (Nasdaq: PHRM -
News) and GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX
index; Nasdaq: GPCB) today announced that the companies have entered
into a co-development and license agreement for satraplatin, the
only oral platinum-based compound in advanced clinical development.
Satraplatin has shown promising safety and efficacy as demonstrated
by significant improvement in progression-free survival (PFS) in a
randomized study of first-line treatment of patients with hormone-
refractory prostate cancer (HRPC) and is currently the subject of a
Phase 3 registrational trial as second-line chemotherapy treatment
for patients with HRPC. Data from the pivotal Phase 3 trial are
expected to form the basis of a Marketing Authorization Application
(MAA) in Europe and a New Drug Application (NDA) in the U.S. for
this indication. Based on data from this trial, Pharmion expects to
file the MAA in Europe in 2007, pending concurrence with the EMEA.
ADVERTISEMENT

Under the terms of the agreement, Pharmion gains exclusive
commercialization rights for Europe, Turkey, the Middle East,
Australia and New Zealand, while GPC Biotech retains rights to the
North American market and all other territories. Pharmion is to
provide an upfront payment of $37.1 million to GPC Biotech,
including an $18 million reimbursement for past satraplatin clinical
development costs and $19.1 million for funding of ongoing and
certain future clinical development to be conducted jointly by
Pharmion and GPC Biotech. The companies will pursue a joint
development plan to evaluate development activities for satraplatin
in a variety of tumor types and will share global development costs,
for which Pharmion has made an additional commitment of $22.2
million, in addition to the $37.1 million in initial payments.
Pharmion will also pay GPC Biotech $30.5 million based on the
achievement of certain regulatory filing and approval milestones,
and up to an additional $75 million for up to five subsequent EMEA
approvals for additional indications. GPC Biotech will also receive
royalties on sales of satraplatin in Pharmion's territories at rates
of 26 to 30 percent on annual sales up to $500 million, and 34
percent on annual sales over $500 million. Finally, Pharmion will
pay GPC Biotech sales milestones totaling up to $105 million, based
on the achievement of significant annual sales levels in the
Pharmion territories. Pharmion and GPC Biotech will lead regulatory
and commercial activities in their respective territories.

"We believe that satraplatin has the potential to provide
significant additional benefits in the well-characterized platinum
treatment class, and we will work closely with GPC Biotech to get
this vital therapy to physicians and patients as quickly as
possible," said Patrick J. Mahaffy, Pharmion's president and chief
executive officer. "Satraplatin represents an important addition to
our product portfolio, complementing our existing products as well
as the global regulatory, clinical development and commercial
organizations that support them."

Bernd R. Seizinger, M.D., Ph.D., chief executive officer of GPC
Biotech, said: "We were very pleased with the significant interest
in satraplatin shown by a large number of pharmaceutical and biotech
firms in the U.S. and Europe. We have selected Pharmion as a partner
because we believe they are ideally suited to help us fully exploit
the potential of satraplatin in Europe and are strongly committed to
continued development of this important compound for a variety of
cancers. The deal structure provides us with significant funding but
still allows GPC Biotech to retain the full commercialization rights
to the U.S. market and other key pharmaceutical markets." Dr.
Seizinger continued: "Pharmion's expertise and its strong oncology
focused commercial infrastructure in Europe and other licensed
territories will be critical in bringing satraplatin to patients in
those countries. With the complementary expertise and the great
respect that our teams have developed for one another, we look
forward to a very productive relationship."

About Satraplatin and its Clinical Development

Satraplatin, an investigational drug, is a member of the platinum
family of compounds. Over the past two decades, platinum-based drugs
have become a critical part of modern chemotherapy treatments and
are used to treat a wide variety of cancers. Unlike the platinum
drugs currently on the market, all of which require intravenous
administration, satraplatin is an orally bioavailable compound and
is given as capsules that patients can take at home. An oral
platinum drug could offer key advantages, including ease of
administration and patient convenience, in a variety of applications.

The results of a clinical study conducted by the European
Organization for Research and Treatment of Cancer (EORTC) evaluating
satraplatin in HRPC were presented at the 2003 Annual Meeting of the
American Society for Clinical Oncology. Fifty patients were
randomized to evaluate the use of satraplatin plus prednisone (n=27)
versus prednisone alone (n=23) for use as a first-line chemotherapy
treatment in HRPC. The study showed that treatment with satraplatin
significantly lengthened progression-free survival (PFS) (p=0.023);
the median PFS was 5.2 months for satraplatin compared to 2.5 months
for the control arm. Additionally, at six months, 41 percent of
patients treated in the satraplatin arm were progression-free
compared to 22 percent of patients in the control arm. A greater
than 50 percent decline in prostate-specific antigen (PSA) was
experienced by 33 percent of patients (9/27) in the satraplatin arm
versus 9 percent of patients (2/23) in the control arm (p=0.046).
The median overall survival time was 15 months for patients treated
in the satraplatin arm versus 12 months for patients in the control
arm (p value not statistically significant). To date, satraplatin is
the only platinum compound that has demonstrated efficacy in a
randomized trial in HRPC.

In the second half of 2003, GPC Biotech launched its phase 3
Satraplatin and Prednisone Against Refractory Cancer (SPARC)
registrational trial. The SPARC trial, which assesses the safety and
efficacy of satraplatin in combination with prednisone as second-
line chemotherapy in patients with HRPC, compares satraplatin plus
prednisone to placebo plus prednisone. This trial is powered to show
improvements in both endpoints of PFS and overall survival. Target
enrollment of 912 patients in this multicenter, multinational,
double-blind, randomized study was achieved earlier this month. GPC
Biotech has initiated the rolling submission of an NDA with the U.S.
Food and Drug Administration (FDA) for satraplatin in combination
with prednisone as a second-line chemotherapy treatment for patients
with HRPC. Assuming continued progress, GPC Biotech expects to
complete the NDA filing in the second half of 2006. Data from the
SPARC trial are also expected to form the basis of an MAA in Europe
for this indication, and, pending concurrence with the EMEA,
Pharmion expects to submit that application in 2007.

In addition, satraplatin has been studied in a range of tumors, and
Phase 2 trials have been completed in HRPC, ovarian cancer and small
cell lung cancer. In other trials, satraplatin appeared to augment
the antitumor effects of radiation therapy, a clinical application
in which satraplatin's oral bioavailability could be particularly
advantageous. A Phase 1/2 study evaluating this combination in
patients with non-small cell lung cancer has been initiated. Several
other Phase 1 and 2 studies evaluating satraplatin in combination
with other therapies and in various cancers are underway or planned.

Conference Call Scheduled

Separate conference calls are planned for Pharmion Corporation at
8:30 a.m. and GPC Biotech at 9:30 a.m. (both times Eastern) to which
participants may listen via live webcast, accessible through each
company's Web site at www.pharmion.com, www.gpc-biotech.com, or via
telephone. Details, including dial-in numbers, will be provided in
separate announcements.

About Pharmion Corporation

Pharmion is a pharmaceutical company focused on acquiring,
developing and commercializing innovative products for the treatment
of hematology and oncology patients in the U.S., Europe and
additional international markets. For additional information about
Pharmion, please visit the company's website at www.pharmion.com.

About GPC Biotech

GPC Biotech AG is a biopharmaceutical company discovering and
developing new anticancer drugs. The Company's lead product
candidate -- satraplatin -- has achieved target enrolment in a Phase
3 registrational trial as a second-line chemotherapy treatment in
hormone-refractory prostate cancer. The U.S. FDA has granted fast
track designation to satraplatin for this indication, and GPC
Biotech has begun the rolling NDA submission process for this
compound. Satraplatin was in-licensed from Spectrum Pharmaceuticals,
Inc. GPC biotech is also developing a monoclonal antibody with a
novel mechanism-of-action against a variety of lymphoid tumors,
currently in Phase 1 clinical development, and has ongoing drug
development and discovery programs that leverage its expertise in
kinase inhibitors. GPC Biotech AG is headquartered in
Martinsried/Munich (Germany). The Company's wholly owned U.S.
subsidiary has sites in Waltham, Massachusetts and Princeton, New
Jersey. For additional information, please visit the Company's Web
site at www.gpc-biotech.com.

This press release contains forward-looking statements, which
express the current beliefs and expectations of management. Such
statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors,
including the timing and effects of regulatory actions, the results
of clinical trials, Pharmion's and GPC Biotech's relative success
developing and gaining market acceptance for any new products, and
the effectiveness of patent protection. There can be no guarantee
that GPC Biotech will receive all of the payments and royalties
outlined in this press release. There can be no guarantee that the
SPARC trial will be completed nor that satraplatin will be approved
for marketing in a timely manner, if at all, nor that, if marketed,
satraplatin will be successful. We direct you to GPC Biotech's
Annual Report on Form 20-F, as amended, for the fiscal year ended
December 31, 2004, Pharmion's most recent filings on Form 10-Q and
10-K, and other reports filed with the U.S. Securities and Exchange
Commission for additional details on the important factors that may
affect the future results, performance and achievements of either
Pharmion or GPC Biotech. Forward-looking statements speak only as of
the date on which they are made and neither Pharmion nor GPC Biotech
undertakes any obligation to update these forward-looking
statements, even if new information becomes available in the future.

---------------------------------------------------------------------
-----------
Source: Pharmion Corporation; GPC Biotech AG

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Sunday, December 18, 2005

PHOENIX DOWNTOWN DEVELOPMENT OFFICE - BIOTECHNOLOGY

PHOENIX DOWNTOWN DEVELOPMENT OFFICE - BIOTECHNOLOGY

Biotechnology and Education

We are committed to furthering the well being of our citizens through biomedical research and direct patient care. The only urban Biomedical Center in Arizona will provide an exceptional location for firms to recruit the most talented doctors and researchers. Let us help you locate or expand your bio company to Phoenix .

Be near the Phoenix Biomedical Campus at Copper Square (PBC), a 30-acre urban research park planned for two million sq. ft. of biomedical related research, laboratory, and academic facilities. Present locates include the following:

TGen/IGC Headquarters

The Translational Genomics Research Institute (TGen) and the International Genomics Consortium (IGC) headquarters opened in December 2004 and is a $46 million, six-story, 170,000 sq. ft. research facility.

The NIDDK Laboratories identify and characterize susceptibility genes for diabetes and obesity as they affect the Native American population

The UA Downtown Phoenix Medical School is expected to begin with 24 students in fall 2006 and expects to expand to 150 students at build out. The former Phoenix Union High School buildings along Van Buren between 5th and 7th streets are being renovated for this project.

The Arizona Biomedical Collaborative (ABC) initiative has its first facility (ABC 1) in early design and will consist of a four story building of approximately 83,000 square feet and will be located just north of the historic buildings along 5th Street . Biomedical academic and research programs at this location will focus on cancer, metabolic diseases and bioinformatics.

Arizona State University Downtown Campus. ASU is partnering with the City of Phoenix to develop a new, urban 2 million square foot campus downtown that will increase the student population to 15,000 students by 2015. The current 160,000 square foot campus offers full degree programs as well as course work towards bachelor's, graduate, and post graduate degrees in business, public administration, nursing, and education.

Science High School - The Phoenix Union High School District is working with the City on the construction of a Science High School which will be located in close proximity to the epicenter of bioscience development -- the Phoenix Biomedical Center at Copper Square (PBC). The Science High School will be located at Pierce and McKinley between 5th and 6th streets. Construction will begin in the fall of 2005 and is scheduled in two phases. The first phase includes the construction of a 2-story, 30,000 SF facility along McKinley followed by a second phase of 17,000 SF of new build and 9,000 SF remodeling of the historic McKinley School. The Science High School is scheduled to open in the fall of 2006 and expects to eventually serve a total of 400 students.

Downtown Development Office

Contact us!
Email: downtown @ phoenix.gov
Phone: 602-534-7143
TTY: 602-534-3476

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Invitrogen Enters into Worldwide Co-Marketing Agreement with genOway Focused on

Invitrogen Enters into Worldwide Co-Marketing Agreement with genOway
Focused on RNAi Services; Deal Positions Companies to Address in
vivo Target Validation Market

CARLSBAD, Calif. & LYON, France Dec. 15, 2005--Invitrogen
Corporation (Nasdaq:IVGN), a provider of essential life science
technologies for disease research and drug discovery and genOway, a
creator of genetically modified biological models today announced
the signing of a co-marketing agreement around RNAi related
services. Under the terms of the agreement, Invitrogen and genOway
will combine Invitrogen's expertise in RNAi research technologies
with genOway's portfolio of transgenesis technologies and RNAi in
vivo experience to create a services platform offering RNAi vector
design through the creation of RNAi transgenic rodent models. Both
companies will share revenues but specific financial terms of the
collaboration were not disclosed.

An important part of the drug discovery research and development
process involves in vivo studies, often performed in animal models.
As RNAi technology has advanced, the need to validate RNAi knockdown
in model systems has been regarded as the next step in the eventual
development of therapeutics based on the technique.

"Combining the services of these two leading RNAi companies will
provide researchers with a complete solution to ensure successful
RNAi research for drug discovery and therapeutic applications," said
Jon Hindar, Senior Vice President of Life Sciences at
Invitrogen. "This broad service offering has the potential to
significantly accelerate target validation studies in disease
research."

"RNAi continues to gain acceptance in drug discovery and development
applications," explained Kader Thiam, Head of Transgenic
technologies of genOway. "Our leading in vivo RNAi technologies are
strengthened by the solid in vitro applications Invitrogen has
developed."

RNAi has rapidly become one of the most widely used techniques in
drug discovery research. Using RNAi technology, scientists can turn
genes "off," enabling them to observe a cell's behavior in the
absence of the targeted gene's protein product. This may lead to
better understanding of disease mechanisms and eventually, better
therapies.

Invitrogen has built a strong RNAi technology portfolio in recent
years, first offering a family of products under the BLOCK-iT(TM)
name in September 2003, including short interfering RNA (siRNA),
kits for creating short hairpin RNA (shRNA), and technologies to
deliver RNAi reagents to cells and tissues. In November 2003,
Invitrogen announced that it had acquired privately-held Sequitur,
Inc. of Natick, Mass. Sequitur brought to Invitrogen Stealth(TM)
technology, a proprietary synthetic RNA molecule that holds
advantages over traditional siRNA in specificity, efficacy,
stability and reducing "off target" effects of silencing. Invitrogen
continues to develop technologies to enhance its comprehensive RNAi
solution to address evolving needs of researchers in the formative
era of the application. This year Invitrogen launched the BLOCK-iT
(TM) pol II miR RNAi expression vector kits and services which
combine the advantages of traditional RNAi vectors with capabilities
for tissue specific expression and multiple target knockdown from
the same transcript.

In three years, genOway has become the leading company for in vivo
RNAi rodent models. Beginning in 2003 genOway launched its Safe RNAi
Transgenesis(TM) technology based on random integration of shRNA
into ES cells. In 2004 the company launched its RNAi Quick Knock-in
(TM) technology that allows targeted insertion of the shRNA into a
specific gene locus, HPRT. Most recently genOway has started
offering a Rat Knock-down R&D program.

About genOway

Based in Lyons, France and Hamburg, Germany genOway is a service
provider fully dedicated to the development of tailor made
transgenic mouse and rat models. The company has established
business relationships with renowned academic research centres,
major biotech companies and leading pharmaceuticals companies.
Operating in 20 countries in Europe, North America and Japan,
genOway is, with respect to staff and clients, the largest company
in its field in Europe. For more information, visit www.genoway.com.

About Invitrogen

Invitrogen Corporation (Nasdaq:IVGN) provides products and services
that support academic and government research institutions and
pharmaceutical and biotech companies worldwide in their efforts to
improve the human condition. The company provides essential life
science technologies for disease research, drug discovery, and
commercial bioproduction. Invitrogen's own research and development
efforts are focused on breakthrough innovation in all major areas of
biological discovery including functional genomics, proteomics,
bioinformatics and cell biology - placing Invitrogen's products in
nearly every major laboratory in the world. Founded in 1987,
Invitrogen is headquartered in Carlsbad, California and conducts
business in more than 70 countries around the world. The company
globally employs approximately 4,800 scientists and other
professionals and had revenues of more than $1 billion in 2004. For
more information, visit www.invitrogen.com.

Safe Harbor Statement

Certain statements contained in this press release are
considered "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, and it is
Invitrogen's intent that such statements be protected by the safe
harbor created thereby. Forward-looking statements include, but are
not limited to: 1) Invitrogen and genOway will combine in vitro and
in vivo applications to form a complete RNAi services platform; 2)
Invitrogen and genOway will share revenues from the co-marketing
agreement; and 3) The collaboration will accelerate target
validation studies in disease research. Such forward-looking
statements are subject to a number of risks, uncertainties and other
factors that could cause actual results to differ materially from
future results expressed or implied by such forward-looking
statements. Potential risks and uncertainties include, but are not
limited to, the risks: a) Details of the agreement are subject to
change according to the evolution of the program; b) Financial terms
of the agreement may vary; and c) The collaboration and co-marketing
agreement may have no significant impact on target validation or
disease research, as well as other risks and uncertainties detailed
from time to time in Invitrogen's Securities and Exchange Commission
filings.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Johnson & Johnson Announces Definitive Agreement to Acquire Animas Corporation,

Johnson & Johnson Announces Definitive Agreement to Acquire Animas
Corporation, an Insulin Delivery Company

Johnson & Johnson

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/

December 16, 2005

- Animas Corporation Expands LifeScan, Inc. Diabetes Management
Offering -

NEW BRUNSWICK, N.J. and WEST CHESTER, Pa., Dec. 16 /PRNewswire-
FirstCall/ -- Johnson & Johnson (NYSE: JNJ) and Animas Corporation
(Nasdaq: PUMP), an insulin delivery company, today announced a
definitive agreement whereby Animas will be acquired in a cash-for-
stock merger transaction. Animas is expected to operate as a stand-
alone entity reporting through LifeScan, Inc., a Johnson & Johnson
company offering blood glucose monitoring systems. The acquisition
affords LifeScan immediate entry into the fast-growing insulin
delivery pump market.

Under the terms of the agreement, Animas stockholders will receive
$24.50 for each outstanding Animas share. The net value of the
transaction as of the anticipated closing date is estimated to be
approximately $518 million based upon Animas' 22 million fully
diluted shares outstanding, net of estimated cash on hand at time of
closing.

The boards of directors of Johnson & Johnson and Animas have
approved the transaction, which is subject to clearance under the
Hart-Scott-Rodino Antitrust Improvements Act, certain foreign
regulatory approvals, Animas stockholder approval and other
customary closing conditions. The transaction is expected to close
in the first quarter of 2006.

Eric Milledge, Johnson & Johnson company group chairman with
responsibility for the LifeScan business, said: "Diabetes is a
worldwide issue, growing at an alarming rate. Our vision is to
create a world without limits for people with diabetes. The
combination of Animas' insulin delivery systems and LifeScan's
glucose monitoring systems will allow us to offer more comprehensive
disease management solutions for our patients. We have worked in
partnership with Animas Corporation since 2003 and know they share
our commitment and passion for advancing the standards of care for
people with diabetes."

Dr. Katherine D. Crothall, chief executive officer and president of
Animas Corporation, said the acquisition would not only be in the
best interest of Animas stockholders and employees, but would
benefit people with diabetes. "Insulin pumps allow significant
improvements in blood glucose control over conventional therapy for
people with insulin-requiring diabetes, reducing the long term
morbidity of diabetes and improving quality of life. We expect that
in combination with LifeScan, our capacity to further contribute to
the management of this disease will be meaningfully increased."

LifeScan, a Johnson & Johnson company and a leading maker of blood
glucose monitoring products, is dedicated to creating a world
without limits for people with diabetes. Every day, people with
diabetes rely on the company's OneTouch(R) Systems for simple
testing and accurate results. In the United States, OneTouch is the
number-one selling brand and is the leader in healthcare
professional recommendations. For company, product and diabetes care
information visit www.LifeScan.com.

Animas, a leading maker of insulin infusion pumps and related
products, is dedicated to improving diabetes management and making
insulin pump therapy easier for patients with insulin requiring
diabetes and healthcare professionals through product innovation,
exemplary customer support and superior customer education. For more
information on Animas, visit www.animascorp.com or call Animas
Corporation at 877-937-7867.

(This press release contains "forward-looking statements" as defined
in the Private Securities Litigation Reform Act of 1995. These
statements are based on current expectations of future events. If
underlying assumptions prove inaccurate or unknown risks and
uncertainties materialize, actual results could vary materially from
the companies' expectations and projections. Risks and uncertainties
include the satisfaction of the conditions to closing, including
receipt of stockholder and regulatory approval; general industry and
conditions and competition; economic conditions, such as interest
rate and currency exchange rate fluctuations; technological advances
and patents attained by competitors; challenges inherent in new
product development, including obtaining regulatory approvals;
domestic and foreign health care reforms and governmental laws and
regulations; and trends toward health care cost containment. A
further list and description of these risks, uncertainties and other
factors can be found in Exhibit 99(b) of Johnson & Johnson's Annual
Report on Form 10- K for the fiscal year ended January 2, 2005, and
in Animas Corporation's Annual Report on Form 10-K for the year
ended December 31, 2004. Copies of said Annual Reports on Form 10-K
are available online at www.sec.gov or on request from the
applicable company. Neither company assumes any obligation to update
any forward-looking statements as a result of new information or
future events or developments.)

Additional Information and Where to Find It:

This material is not a substitute for the proxy statement Animas
Corporation will file with the Securities and Exchange Commission.
Investors are urged to read the proxy statement when it becomes
available, because it will contain important information. The proxy
statement and other documents, which will be filed by Animas with
the Securities and Exchange Commission, will be available free of
charge at the SEC's website, www.sec.gov, or by visiting Animas'
website at www.animascorp.com.

Animas and certain of its directors, executive officers and certain
other members of its management may be deemed to be soliciting
proxies from Animas' stockholders in connection with the proposed
transaction. Investors may obtain a detailed list of names,
affiliations and interests of Animas participants in the
solicitation of proxies of Animas' stockholders by reading the proxy
statement when it becomes available.

SOURCE Johnson & Johnson

http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.imhcaz.com/
http://www.mail-archive.com/biotech-news@yahoogroups.com/
http://www.mail-archive.com/biotech-
news@yahoogroups.com/maillist.html

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Biotech Pioneer -- Retiring teacher was biotech trailblazer

SignOnSanDiego.com > News > North County -- Retiring teacher was biotech trailblazer

Retiring teacher was biotech trailblazer

Biotech
Biotech

By Triveni Sheshadri
UNION-TRIBUNE COMMUNITY NEWS WRITER
December 18, 2005

SAN MARCOS – On a recent afternoon, Jan Mongoven led about a dozen students in his honors biotechnology lab class through the process of making a gel to separate DNA strands of E. coli bacteria.

That was one of the last times he stood before a classroom at San Marcos High School.

Mongoven retired Friday and bade goodbye to his lab, students, colleagues and the only school he had known in his 32-year teaching career.

He is credited with starting the county's first honors genetics class at the high school level.

Mongoven said the idea sprang from a student's suggestion.

"It was back in 1979," he said. "I had finished teaching an anatomy class and there were students who were eager for more. One of them said, 'Why don't we do genetics?'"

The class became so popular that the school added four sections. Later in 1994, Mongoven started the honors biotech lab class that combines molecular and microbiology and DNA science.

Mongoven, 55, was named California Teacher of the Year in 2000, an honor he shared with four other teachers in the state.

The career trajectory of many of his students is a testament to Mongoven's influence as a teacher. Several have earned advanced degrees and are pursuing successful careers in biology, biotechnology, medicine and teaching.

High Tech
Funny Jokes
Funny Jokes
Funny Jokes
Arizona Entrepreneurs

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Novartis plans all-cash counter bid for Berna Biotech - report - Forbes.com

Novartis plans all-cash counter bid for Berna Biotech - report - Forbes.com

Novartis plans all-cash counter bid for Berna Biotech - report
12.18.2005, 09:53 AM

ZURICH (AFX) - Novartis AG plans to make an all-cash counter bid for Swiss vaccines maker Berna Biotech AG, Switzerland's SonntagsZeitung reported citing unnamed sources.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Cuba cutting `world class' trail in biotech research

Chicago Tribune | Cuba cutting `world class' trail in biotech research

Cuba cutting `world class' trail in biotech research
Well-funded government labs enable Castro's cash-starved nation to produce high-quality vaccines and medications for a global market

By Gary Marx
Tribune foreign correspondent
Published December 18, 2005

HAVANA -- On the outskirts of Havana sits a cluster of drab buildings that are part of an effort to propel Cuba to the forefront of biotechnology even as its population struggles with blackouts, shortages and crumbling infrastructure.

Known as the Center for Genetic Engineering and Biotechnology, or CIGB, the institute is one of 52 government facilities dedicated to human, animal and agricultural research that have recorded a string of successes.

Using more than $1 billion in state funding, Cuban scientists have produced a hepatitis B vaccine sold in more than 30 countries and streptokinase, a potent enzyme that dissolves blood clots and improves the survival rate of heart attack victims. The country also makes recombinant interferon that strengthens the immune system of cancer patients, and a meningitis B vaccine.

Arizona Biotech News
Biotech News
Arizona Entrepreneurs
Arizona Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Thursday, December 15, 2005

[ biotech news ] GPC Biotech Begins Rolling NDA Submission for Lead Drug Candidate Satraplatin

http://www.arizonabiotech.com/

GPC Biotech Begins Rolling NDA Submission for Lead Drug Candidate
Satraplatin

MARTINSRIED/MUNICH, GERMANY -- -- 12/15/2005 -- Waltham, Mass. and
Princeton, N.J. -- GPC Biotech AG (Frankfurt: GPC) (TecDAX index)
(NASDAQ: GPCB) today announced that the Company has begun the
rolling submission of a New Drug Application (NDA) with the U.S.
Food and Drug Administration (FDA) for satraplatin in combination
with prednisone as a second-line chemotherapy treatment for patients
with hormone-refractory prostate cancer (HRPC). To begin the rolling
NDA process, the Company has submitted to the FDA the chemistry,
manufacturing and controls -- or CMC -- section of the NDA filing.

"It is very gratifying for us to begin the rolling NDA submission
process for our lead drug candidate satraplatin," said Bernd R.
Seizinger, M.D., Ph.D., Chief Executive Officer. "Building on our
recent achievement of reaching target enrollment in our Phase 3
registrational trial, it marks another important milestone in the
development process of satraplatin as a potential new treatment
option for patients with hormone-refractory prostate cancer. We are
focused on working with regulatory authorities to efficiently move
our compound through the filing and review process, with the
ultimate goal of making satraplatin available to patients as quickly
as possible."

The rolling submission process enables companies that have been
granted "fast track" designation by the FDA to submit sections of
the NDA to the agency as they become available, allowing the review
process to begin before the complete dossier has been submitted.
Under U.S. regulations, within sixty days after the receipt of such
a submission, the FDA will determine whether that application may be
filed. The filing of an application means that the FDA has
determined that the application is sufficiently complete to permit a
substantive review.

The FDA's fast track programs are intended to expedite the review of
drugs to treat serious or life-threatening conditions and that
demonstrate the potential to address unmet medical needs. The FDA
granted fast track designation to satraplatin as a second-line
chemotherapy treatment for patients with HRPC in September 2003.

About Satraplatin

Satraplatin, an investigational drug, is a member of the platinum
family of compounds. Over the past two decades, platinum-based drugs
have become a critical part of modern chemotherapy treatments and
are used to treat a wide variety of cancers. Worldwide sales of
these drugs exceeded $2.2 billion in 2004. Unlike the platinum drugs
currently on the market, all of which require intravenous
administration, satraplatin is an orally bioavailable compound and
is given as capsules that patients can take at home. An oral
platinum drug could offer key advantages, including ease of
administration and patient convenience, in a variety of
applications. Target enrollment has been achieved in a Phase 3
registrational trial -- the SPARC trial -- as a second-line
chemotherapy treatment for HRPC. GPC Biotech has completed a Special
Protocol Assessment with the U.S. FDA and has received a Scientific
Advice letter from the European regulatory authority, the European
Medicines Agency (EMEA). The FDA has also granted fast track
designation to satraplatin for this indication. Satraplatin was in-
licensed from Spectrum Pharmaceuticals, Inc.

Phase 2 trials have been completed in HRPC, ovarian cancer and small
cell lung cancer. Promising early clinical results have also been
shown when satraplatin is combined with radiation therapy, and a
Phase 1/2 study evaluating this combination in patients with non-
small cell lung cancer has been initiated. Several other studies
evaluating satraplatin in combination with other therapies and in
various cancers, including breast and lung cancers, are underway or
planned. Further information on satraplatin can be found in the
Anticancer Programs section of the Company's Web site at www.gpc-
biotech.com.

GPC Biotech AG is a biopharmaceutical company discovering and
developing new anticancer drugs. The Company's lead product
candidate -- satraplatin -- is currently in a Phase 3 registrational
trial as a second-line chemotherapy treatment in hormone-refractory
prostate cancer following completion of a Special Protocol
Assessment by the U.S. FDA and receipt of a Scientific Advice letter
from the European central regulatory authority, EMEA. The FDA has
also granted fast track designation to satraplatin for this
indication. The Company is also developing a monoclonal antibody
with a novel mechanism-of-action against a variety of lymphoid
tumors, currently in Phase 1 clinical development, and has ongoing
drug development and discovery programs that leverage its expertise
in kinase inhibitors. GPC Biotech has a multi-year alliance with
ALTANA Pharma AG working with the ALTANA Research Institute in the
U.S., which provides GPC Biotech with revenues through mid-2007. GPC
Biotech AG is headquartered in Martinsried/Munich (Germany). The
Company's wholly owned U.S. subsidiary has research and development
sites in Waltham, Massachusetts and Princeton, New Jersey. For
additional information, please visit the Company's Web site at
www.gpc-biotech.com.

This press release may contain projections or estimates about plans
and objectives relating to our future operations, products, or
services; future financial results; or assumptions underlying or
relating to any such statements. These statements are forward-
looking and are subject to risks and uncertainties, many of which
are beyond our control. Actual results could differ materially
depending on a number of factors, including the timing and effects
of regulatory actions, the results of clinical trials, the Company's
relative success developing and gaining market acceptance for any
new products, and the effectiveness of patent protection. There can
be no guarantee regarding the results of the SPARC trial or other
ongoing studies with satraplatin. There can be no guarantee that the
NDA filing for satraplatin will not be completed nor that
satraplatin will be approved for marketing in a timely manner, if at
all. We direct you to the Company's Annual Report on Form 20-F, as
amended, for the fiscal year ended December 31, 2004 and other
reports filed with the U.S. Securities and Exchange Commission for
additional details on the important factors that may affect the
Company's future results, performance and achievements. The Company
disclaims any intent or obligation to update these forward-looking
statements or the factors that may affect the Company's future
results, performance or achievements, even if new information
becomes available in the future.

---------------------------------------------------------------------
-----------

For further information, please contact:

GPC Biotech AG
Fraunhoferstr. 20
82152 Martinsried/Munich, Germany

Martin Braendle
Associate Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com

In the U.S.: Laurie Doyle
Associate Director, Investor Relations & Corporate Communications
Phone: +1 781 890 9007 X267
usinvestors@gpc-biotech.com

Additional Media Contacts:

In Europe:
Maitland Noonan Russo
Brian Hudspith
Phone: +44 (0)20 7379 5151
bhudspith@maitland.co.uk

In the U.S.:
Euro RSCG Life NRP
Emily Poe
Phone: +1 212 845 4266
emily.poe@eurorscg.com

SOURCE: GPC Biotech AG

http://groups.yahoo.com/group/biotech-news/
http://home.att.net/~seo/search-engine-marketing-firms.html
http://www.arizonaentrepreneurs.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Xcyte Therapies and Invitrogen Announce Signing of Asset Purchase Agreement; Inv

Xcyte Therapies and Invitrogen Announce Signing of Asset Purchase
Agreement; Invitrogen to Acquire Xcyte's T Cell Expansion Technology

SEATTLE & CARLSBAD, Calif. Dec 15, 2005 - Xcyte Therapies, Inc.
(Xcyte) (Nasdaq:XCYT) (Nasdaq:XCYTP) and Invitrogen Corporation
(Nasdaq:IVGN) today announced they have entered into a definitive
agreement for Invitrogen to acquire Xcyte's T cell expansion
technology, known as the "Xcellerate Process." The acquired assets
will include intellectual property, the clinical data generated by
Xcyte in the course of six clinical trials of its lead product,
Xcellerated T Cells, as well as raw materials and equipment.

Under the terms of the definitive agreement, upon the closing of the
transaction Invitrogen will make a $5 million cash payment to Xcyte.
In addition, Xcyte is entitled to receive a percentage of any
sublicensing revenue Invitrogen derives from the further licensing
of Xcyte's intellectual property for therapeutic purposes, subject
to certain minimum revenue requirements.

"Xcyte has had a long and productive collaboration with Dynal
Biotech for the production of Xcyte Dynabeads, the proprietary
magnetic bead Xcyte has used to expand and activate T cells for
potential therapeutic indications in oncology and infectious
disease," said Robert L. Kirkman, M.D., Acting President and Chief
Executive Officer of Xcyte. "With Xcyte's decision earlier this year
to pursue a new strategic direction and Invitrogen's acquisition of
Dynal, Invitrogen was our first choice to acquire the Xcellerate
Technology. We are very pleased that they have agreed to do so and
will continue to make this exciting and important approach to
immunotherapy available to the research community."

"To Invitrogen, this transaction represents a cornerstone in a
broader effort to substantially increase our offering to customers
working within immunotherapy. We firmly believe T-cell based therapy
will become an important contributor in the efforts to fight disease
in the future," said Dr. Oystein Amellem, Business Area Manager for
Invitrogen's Dynal Bead Based Separation group. "Expansion of T
cells ex vivo using Dynabeads(R) to which anti-CD3 and anti-C28
monoclonal antibodies are linked may prove useful for the treatment
of cancer, infectious diseases and recently autoimmune diseases. We
are very excited to be able to bring this unique technology to our
customers in the emerging field of cell-based immunotherapy."

The transaction is subject to certain customary closing conditions,
including the approval of Xcyte's stockholders.

Additional Information

Xcyte today separately announced an agreement to acquire all of the
capital stock of Cyclacel Limited, a wholly-owned subsidiary of
Cyclacel Group plc. In conjunction with that transaction, Xcyte
plans to file a registration statement containing a proxy
statement/prospectus with the Securities and Exchange Commission.
Xcyte will also include in its proxy statement/prospectus a
resolution for stockholder approval of the sale of its T cell
expansion technology to Invitrogen Corporation. XCYTE'S STOCKHOLDERS
AND OTHER INVESTORS ARE ENCOURAGED TO READ THE PROXY
STATEMENT/PROSPECTUS, INCLUDING ANY SUBSEQUENT AMENDMENTS OR
SUPPLEMENTS TO THE PROXY STATEMENT/PROSPECTUS, WHEN IT BECOMES
AVAILABLE, AS IT WILL CONTAIN IMPORTANT INFORMATION. Copies of the
proxy statement/prospectus will be available free of charge at the
Securities and Exchange Commission website (www.sec.gov) or from
Xcyte Therapies, Inc., 1124 Columbia Street, Suite 130, Seattle, WA
98104, Attention: Investor Relations, Telephone: 206-262-6200.

Xcyte and its executive officers and directors may be deemed to be
participants in the solicitation of proxies from stockholders of
Xcyte with respect to the proposed transactions. Information
regarding such officers and directors is included in Xcyte's proxy
statement for its 2005 Annual Meeting of Stockholders filed with the
Securities and Exchange Commission on April 29, 2005, and will be
included in the proxy statement/prospectus referred to above. These
documents are or will be available free of charge at the Securities
and Exchange Commission website (www.sec.gov) or from Investor
Relations at Xcyte at the address referred to above.

Forward-Looking Statements

Certain statements contained in this press release are
considered "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, and it is Xcyte's
and Invitrogen's intent that such statements be protected by the
safe harbor created thereby. Forward-looking statements include, but
are not limited to, statements regarding the proposed acquisition by
Invitrogen of Xcyte's T cell expansion technology, the purchase
price payments to be made upon the closing of such transaction and
that Xcyte will issue a proxy statement/prospectus seeking
stockholder approval. Such forward-looking statements are subject to
a number of risks, uncertainties and other factors that could cause
actual results to differ materially from future results expressed or
implied by such forward-looking statements. Potential risks and
uncertainties include, but are not limited to, the risks that
Xcyte's stockholders will not approve the proposed transaction, the
failure to obtain required regulatory approvals, if any, that the
closing of the transaction will be delayed or the transaction will
not close, that the purchase price payment will not be made or that
Xcyte and Cyclacel will not consummate their proposed transaction.
Further information about the risks and uncertainties faced by both
Xcyte Therapies and Invitrogen Corporation is contained in their
respective periodic filings with the Securities and Exchange
Commission.

About Xcyte Therapies

From its inception in 1996 until early July 2005, Xcyte Therapies
devoted substantially all of its efforts to the research and
development of therapies that harness the power of the immune system
to treat cancer and other serious illnesses. Xcyte derived its
therapeutic products from a patient's own T cells, which are cells
of the immune system that orchestrate immune responses and can
detect and eliminate cancer cells and infected cells in the body.
Xcyte used its patented and proprietary Xcellerate Technology to
generate activated T cells, called Xcellerated T Cells, from blood
that is collected from the patient. Activated T cells are T cells
that have been stimulated to carry out immune functions. The
Xcellerate Technology is designed to rapidly activate and expand the
number of the patient's T cells outside of the body. These
Xcellerated T Cells are then administered to the patient.

About Invitrogen

Invitrogen Corporation (Nasdaq:IVGN) provides products and services
that support academic and government research institutions and
pharmaceutical and biotech companies worldwide in their efforts to
improve the human condition. The company provides essential life
science technologies for disease research, drug discovery and
commercial bio-production. Invitrogen's own research and development
efforts are focused on breakthrough innovation in all major areas of
biological discovery, including functional genomics, proteomics, bio-
informatics and cell biology, placing Invitrogen's products in
nearly every major laboratory in the world. Founded in 1987,
Invitrogen is headquartered in Carlsbad, Calif., and conducts
business in more than 70 countries around the world. The company
globally employs approximately 4,800 scientists and other
professionals, and had revenues in excess of $1 billion in 2004.
Information about Invitrogen is available on the Web at
www.invitrogen.com.

Xcyte(R), Xcellerate(R) and Xcellerated T Cells(R) are registered
trademarks and Xcyte Therapies(TM) is a trademark of Xcyte
Therapies, Inc.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://home.att.net/~seo/search-engine-marketing-firms.html
http://www.arizonaentrepreneurs.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Top biotech co Amgen to buy Abgenix for $2.2bn- The Economic Times

Top biotech co Amgen to buy Abgenix for $2.2bn- The Economic Times

Top biotech co Amgen to buy Abgenix for $2.2bn
DEENA BEASLEY

REUTERS[ FRIDAY, DECEMBER 16, 2005 01:18:30 AM]
NRI Special Offer!
LOS ANGELES: Amgen, the world’s largest biotechnology company, said on Wednesday that it plans to acquire Abgenix for about $2.2bn in cash, giving it full control of the cancer drug the two are developing. The news sent shares of both companies higher in after-hours trading.

If approved by regulators, the drug, called panitumumab, would be the first cancer treatment from Amgen. The company has billions of dollars in sales of products that treat anemia and other side effects of chemotherapy.

“Panitumumab was the key driver for this transaction,” Roger Perlmutter, head of research and development at Amgen, said on a conference call.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Tuesday, December 13, 2005

[ biotech news ] Great Lakes Entrepreneur's Quest Adds Life Science Experts to Coaching Team

Great Lakes Entrepreneur's Quest Adds Life Science Experts to
Coaching Team

ANN ARBOR, Mich., Dec. 13 -- The Great Lakes Entrepreneur's Quest
(GLEQ) announces the addition of two Life Science experts to its
coaching team. Dr. Rochelle Hanley and Marianne Andreach are joining
a team of 30 GLEQ business coaches to strengthen its Life Sciences
coaching competencies. Entrepreneurs competing in the GLEQ business
plan competition can receive tremendously valuable coaching from
industry experts. Teams are matched with coaches depending on their
specific industry and needs as a business start-up.

"The Fall Cycle has been extremely robust, with a particularly
strong level of Life Science start-ups," said Art DeMonte, GLEQ
Executive Director. "We are delighted to have the caliber of talent
Rochelle and Marianne bring to the coaching team to assist Life
Science teams with their business plans and commercialization
efforts."

Dr. Hanley is coaching Fall Cycle teams NeuRxus Inc. and Media
Balance, Inc., while Ms. Andreach will work with ThreeFold Sensors,
Inc. and Tiresias Medical. Over 50 teams are now competing in the
Great Lakes Entrepreneur's Quest Business Plan competition. Winners
will be announced on February 7th, 2006.

About our Coaches:

1. Dr. Rochelle Hanley has held a variety of senior executive
positions at Pfizer, Parke-Davis and Glaxo Wellcome. She brings
broad expertise in drug development and a strong track record in
clinical development with emphasis on metabolic and cardiovascular
therapeutics. Additionally, Rochelle was assistant professor at The
University of Texas Health Science Center and at Duke University
Medical Center. She earned her M.D. degree at the University of
Michigan after completion of her B.A. in Molecular and Cell Biology
at Smith College.

2. Marianne Andreach has been in the pharmaceutical industry for 22
years, working in a variety of positions at big pharma companies
Bristol-Myers Squibb and Parke-Davis, biotech firms -- Esperion
Therapeutics -- and currently at Esperion Therapeutics, Division of
Pfizer Global Research and Development. During her career, Marianne
has mastered a wide spectrum of disciplines including Discovery,
Sales, Marketing, Medical Education, Product Planning and Medical
Affairs.

About the Great Lakes Entrepreneur's Quest (GLEQ)

The GLEQ is a nonprofit 501(c)(3) educational program designed to
accelerate the formation of high-growth companies across Michigan.
Anyone who lives, works or attends school in Michigan can
participate in the competitions and educational programs at no cost.

The GLEQ sponsors a statewide business plan competition. The Quest
is structured into two distinct maturity "paths": companies with
more developed businesses compete in the Emerging Company (EC) path
while teams with new or less developed business ideas compete in the
New Business Ideas (NBI) path.

The EC teams must complete and submit an 8 to 12 page business plan,
while the NBI teams must develop and submit a five-page executive
summary describing their business or business idea. The GLEQ
provides the help of coaches and educational programs to assist all
entrepreneurs with their business plans. A cash award is given to
the winner of the EC path in the spring, while additional cash and
in-kind awards are provided to the EC and NBI winners.

The GLEQ's primary sponsors are the Ann and Carman Adams Fund of the
Community Foundation for Southeastern Michigan, Wayne State
University, Apjohn Group, Southwest Michigan First, and Esperance
BioVentures. Founded in 2000, the GLEQ has awarded $600,000 in prize
money during the first four years of its annual business plan
competition and provided over a thousand hours of free training and
coaching. Additional information is available at http://www.gleq.org
or by calling Art DeMonte, Executive Director, at 734-913-0090.

To register for training classes, learn more about the competition's
eligibility requirements or register for the Fall Cycle please visit
http://www.gleq.org .

---------------------------------------------------------------------
-----------
Source: Great Lakes Entrepreneur's Quest

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

TimesDispatch.com | Insmed drug wins approval

TimesDispatch.com | Insmed drug wins approval

Insmed drug wins approval
Growth-hormone medicine could help the Henrico firm expand its product line

BY JEFFREY KELLEY
TIMES-DISPATCH STAFF WRITER Dec 13, 2005

Insmed Inc. said yesterday evening that federal regulators have approved its drug iPlex, propelling the Henrico County firm into a small but competitive marketplace.

The Food and Drug Administration also granted Insmed "orphan-drug" status on iPlex, used to treat children with a growth-hormone deficiency. An approved competing drug has the same status, which gives a company seven years of marketing exclusivity for drugs that treat rare diseases.

At 7:30 last night, Insmed's stock was trading at $2.32, up 55.7 percent from the day's close.

"Today marks the beginning of a new treatment paradigm for treating children with [short stature] . . . This is also an exciting transition for Insmed," Geoffrey Allan, president and chief executive of Insmed, said in a statement. iPlex is expected to launch in the second quarter next year, the company said.

Mark A. Herzog, executive director of the Virginia Biotechnology Association, and Robert T. Skunda, president and chief executive of the Virginia BioTechnology Research Park, praised the Insmed approval yesterday as a step forward for the state biotechnology arena.

Insmed is the first alumnus of the 10-year- old park to win approval of a drug, they said.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Diamyd Medical Broadens Diabetes Pipeline With Acquisition Of Nurel Therapeutics

Diamyd Medical Broadens Diabetes Pipeline With Acquisition Of Nurel
Therapeutics

STOCKHOLM, Sweden, Dec. 13, 2005 -- Diamyd Medical AB (OMX:DIAMB)
emerged as a global biotechnology company as shareholders approved
the acquisition of Nurel Therapeutics, Inc. at a General Assembly
Meeting in Stockholm yesterday. The Pittsburgh, PA- based biotech
adds significantly to Diamyd Medical's pipeline for diabetes which
now includes both a therapeutic vaccine for autoimmune type 1 and
type 2 diabetes as well as therapies for diabetic pain. The merger
is expected to close on Friday, December 16.

Diamyd shareholders approved the issuance of common stock to Nurel
shareholders in connection with the merger. Nurel shareholders will
receive a total of about 223,208 Diamyd B shares. This reflects an
assumed Diamyd B share value of SEK 55, which corresponded to a 15%
premium as of the deal signature date, the 21st of November. In
addition, Diamyd shareholders approved the issuance of an additional
approximate 110,000 Diamyd shares against convertible loans used
previously to finance Nurel, which in total represents a dilution of
about 4% to Diamyd shareholders. The merger will create strong
synergies between Diamyd Medical and Nurel, while having little
effect on Diamyd's financial position and burn rate.

"Nurel and Diaymd Medical both work in diabetes and both have a GAD-
based lead compound. We differ in that the GAD is used for two
totally different and non-overlapping aspects of diabetes: (1) the
treatment of the actual disease itself, and (2) the treatment of
pain resulting from diabetes. The acquisition of Nurel brings a
tremendous amount of synergy to the table, which makes the deal very
attractive and beneficial to our shareholders," says Anders Essen-
Moller, President and CEO of Diamyd Medical.

Michael Christini, president of Nurel Therapeutics noted, "This is a
significant milestone for both companies. The merger creates a
global biotechnology company with combined portfolios with a strong
diabetes franchise aimed not only at treating diabetes but also the
complications associated with the disease, including peripheral
nerve pain. We are enthusiastic for the synergies this merger will
create and look forward to advancing the product portfolio through
the clinic in both Europe and the U.S."

Nurel has previously received convertible debt funding from
Pittsburgh-based investment groups including UPMC Health Ventures, a
venture fund owned by UPMC, the premier health system in Western
Pennsylvania, USA. Nurel has also received convertible debt funding
from Innovation Works, an economic development organization in
Western Pennsylvania and from the Pittsburgh Life Sciences
Greenhouse, a Western Pennsylvania public/private partnership that
invests in and supports the growth of life sciences companies.

"It's gratifying to see the cutting edge technologies and treatments
developed at the University of Pittsburgh find their way into the
mainstream," said Chuck Bogosta, Managing Director of the University
of Pittsburgh Medical Center's Strategic Business Initiatives. "UPMC
is pleased to have been an early investor in Nurel. The treatments
developed at the university will benefit diabetes patients
everywhere, and we look forward to the new venture flourishing. We
are particularly happy that Diamyd has chosen to open its North
American headquarters in the Pittsburgh region because we believe
strongly that it is an area that has the medical and entrepreneurial
resources needed to help Diamyd's enterprises continue to grow."

Diamyd Medical is focused on developing treatments for diabetes,
both type 1 and type 2, via GAD protein therapy. Its lead drug
candidate, Diamyd(tm), is designed to reduce the need of insulin
injections and prevent the destruction of beta cells. Furthermore,
it may allow for regeneration of beta cells in a non-autoimmune
environment, thus setting the stage for a cure of the disease. The
Company is conducting two clinical trials concurrently. The first
trial is a double blind Phase IIb study in 70 children and
adolescents; results will be announced in about 8 months. The second
study currently underway is a Phase II/III study conducted in 160
adult type 2 diabetes patients with autoantibodies to beta cells;
results will be announced 10 months thereafter. Both studies are
running at 25 clinics in Sweden and all patients are included and
treated. The two studies were initiated after positive results in a
first double blind dose finding Phase II study in 47 type 2 diabetes
patients.

Currently, there is a major unmet need for a drug to treat chronic
pain in patients suffering from diabetic neuropathy and spinal
injury pain, and cancer pain. Preclinical studies show efficacy in
industry accepted animal models and Nurel plans to file an IND in
about 12 months.

Nurel has identified two candidate molecules for the treatment of
chronic pain: (1) GAD for treatment of chronic pain due to diabetes,
and spinal cord injury; and (2) Enkephalin for cancer pain. These
molecules will be delivered to patients with Nurel's proprietary
Nerve-Targeted Gene Delivery System, for which an extensive
intellectual property portfolio has been licensed from the
University of Pittsburgh.

In addition to the pipeline of pain products, Nurel's proprietary
Nerve-Targeted Gene Delivery System for GAD may potentially be used
in several other GAD-related disorders such as schizophrenia,
anorexia, ALS, Parkinson's and epilepsy. This makes it possible to
fully explore the potential of Diamyd Medical's exclusive license to
the recombinant GAD65-molecule.

Nurel's Nerve-Targeted Gene Delivery System can also be used for
targeted deliveries of third party molecules. Nurel is discussing
outlicensing deals with such parties, just as Diamyd is discussing
outlicensing of its GAD65 technology with Neurologix Inc for
Parkinson's.

One early use for Nurel's Nerve-Targeted Gene Delivery System is in
the treatment of gliablastoma, a usually fatal form of brain cancer.
Funding for this project was committed by the U.S. National
Institutes of Health in the form of approximately $1.4 million in
Federal grants to support GMP manufacturing and Phase 1 trials for
NC3, a Nurel multi-gene cancer product. Filing of an IND for first
clinical trials for NC3 is anticipated within the next 12 months.

About Nurel Therapeutics

Nurel therapeutics has developed an innovative new Nerve-Targeted
Gene Delivery System that is specifically designed for delivery of
therapeutic molecules to the nerve system for a large variety of
diseases. Nurel is pursuing development of proprietary therapeutics
focused on treating pain including neuropathic pain that results
from nerve damage due to diabetes or spinal cord injury and cancer
pain; preventing nerve damage by protecting nerve fibers from the
long term affects of diabetes, and an innovative therapy to treat
glioblastoma and other cancers. The Company's first products, NG2
(HSV-GAD) and NPE2 (HSV-enkephalin), deliver therapeutic proteins to
the peripheral nerve cells and effectively reduce pain in industry-
standard animal models. Clinical testing in humans suffering from
chronic pain is scheduled to begin in 2007. Additional information
regarding Nurel can be found at www.nureltx.com.

About Diamyd Medical

Diamyd Medical is registered on the Stockholm Stock Exchange O List
(OMX:DIAMB). An application has been submitted to trade the shares
in the U.S. via a Level 1 ADR Program. The Company conducts
therapeutic development based on its GAD (glutamic acid
decarboxylase) technology platform. GAD is an enzyme that converts
the excitatory neurotransmittor glutamate to the inhibitory
transmittor GABA. In this context GAD may have an important role in
CNS-related disease states. GAD is also a target pancreatic beta
cell autoantigen in autoimmune diabetes, such autoimmunity leading
to development of insulin-dependence. Diamyd Medical's furthest
developed project is Diamyd, which is currently employed in two
ongoing clinical trials of both Type 2 and Type 1 diabetes which are
follow-ons of first successful dose finding Phase II trial which is
now in an open follow up phase.

Diamyd Medical AB (publ). Linnegatan 89 B, SE-115 23 Stockholm,
Sweden. Tel: 08-661 00 26, fax: 08-661 63 68 or email:
info@diamyd.com. Corp ID: 556530-1420.

This information includes statements concerning historical, present
and forward-looking items and is to the "best of knowledge" of the
management of Diamyd Medical and the actual status and results
achieved by the Company may differ materially from these statements.
The Company assumes no obligation to update these statements to
reflect actual results, changes in assumptions or changes in other
factors affecting such statements. The Company's Press Releases,
Quarterly Reports and Annual Reports ("Information") are
translations from the Swedish originals. No guarantees are made that
the translation is free from errors.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Independent Data Monitoring Board Holds Third Review of Safety Data

Independent Data Monitoring Board Holds Third Review of Safety Data

Recommends Satraplatin Phase 3 Registrational Trial Continue as
Planned

IRVINE, Calif., December 13, 2005 -- Spectrum Pharmaceuticals, Inc.
today announced that the independent Data Monitoring Board (DMB) for
the satraplatin Phase 3 registrational trial SPARC (Satraplatin and
Prednisone Against Refractory Cancer) in second-line chemotherapy
for hormone-refractory prostate cancer held its third meeting on
December 12, 2005 to review safety data from the ongoing study. The
Charter of the DMB requires that the group meet at least twice each
year. The DMB reviewed the safety data from the first 592 patients
who had been randomized in the trial and had completed at least one
cycle of treatment. After reviewing the data, the DMB reported that
the design and conduct of the trial remain sound and recommended
that the trial continue as planned. The interim efficacy analysis by
the DMB is expected to occur, as previously stated, by the end of
the first quarter of 2006.

As reported earlier this month, GPC Biotech AG, Spectrum's co-
development partner, has achieved its target accrual of 912 patients
in the SPARC trial.

About Satraplatin

Satraplatin, an investigational drug, is a member of the platinum
family of compounds. Over the past two decades, platinum-based drugs
have become a critical part of modern chemotherapy treatments and
are used to treat a wide variety of cancers. Worldwide sales of
these drugs exceeded $2.2 billion in 2004. Unlike the platinum drugs
currently on the market, all of which require intravenous
administration, satraplatin is an orally bioavailable compound and
is given as capsules that patients can take at home. An oral
platinum drug could offer key advantages, including ease of
administration and patient convenience, in a variety of
applications. The Phase 3 registrational trial -- the SPARC trial --
as a second-line chemotherapy treatment for hormone-refractory
prostate cancer (HRPC) has just reached its target enrollment. The
FDA has also granted fast track designation to satraplatin for this
indication.

Phase 2 trials have been completed in HRPC, ovarian cancer and small-
cell lung cancer. Promising early clinical results have also been
shown when satraplatin is combined with radiation therapy, and a
Phase 1/2 study evaluating this combination in patients with non-
small cell lung cancer has been initiated. Several other Phase 1 and
Phase 2 studies evaluating satraplatin in combination with other
therapies and in various cancers are underway or planned. Further
information on satraplatin can be found at the Company's website at
www.spectrumpharm.com or in the Anticancer Programs section of GPC
Biotech's website at www.gpc-biotech.com.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals is a specialty pharmaceutical company
engaged in the business of acquiring, developing and commercializing
prescription drug products for the treatment of cancer and other
unmet medical needs. By leveraging its operational flexibility and
regulatory proficiency, and using the extensive research and
development capabilities of its strategic alliance partners,
Spectrum has built a diversified portfolio of proprietary and
generic drug products in various stages of development and
regulatory approval. For more information, please visit our website
at www.spectrumpharm.com.

Forward-looking statements

This press release may contain forward-looking statements regarding
future events and the future performance of Spectrum Pharmaceuticals
that involve risks and uncertainties that could cause actual results
to differ materially. These statements include but are not limited
to statements that relate to our business and its future, the
Company's operational flexibility and regulatory proficiency, the
extensive research and development capabilities of the Company's
strategic alliance partners, that satraplatin could offer key
advantages, including ease of administration and patient
convenience, in a variety of applications, the initiation of several
other Phase 1 and Phase 2 studies evaluating satraplatin in
combination with other therapies and in various cancers and any
statements that relate to the intent, belief, plans or expectations
of Spectrum or its management, or that are not a statement of
historical fact. Risks that could cause actual results to differ
include the possibility that our existing and new drug candidates,
may not prove safe or effective, the possibility that our existing
and new drug candidates may not receive approval from the FDA, and
other regulatory agencies in a timely manner or at all, the
possibility that our existing and new drug candidates, if approved,
may not be more effective, safer or more cost efficient than
competing drugs, the possibility that past results (including
results related to the safety of the Phase 3 satraplatin trial) will
not be indicative of future results, the possibility that price and
other competitive pressures may make the marketing and sale of our
generic drugs not commercially feasible, the possibility that our
efforts to acquire or in-license and develop additional drug
candidates may fail, our lack of revenues, our limited experience in
establishing strategic alliances, our limited marketing experience,
our limited experience with the generic drug industry, our
dependence on third parties for clinical trials, manufacturing,
distribution and quality control and other risks that are described
in further detail in the Company's reports filed with the Securities
and Exchange Commission.

http://www.arizonabiotech.com/
http://www.imhcaz.com/
http://groups.yahoo.com/group/biotech-news/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Work about to start on biotech center

Work about to start on biotech center

Arizona's quest to become a biotech research powerhouse will take a
big step forward next week when construction begins on a long-awaited
biosciences building in downtown Phoenix.

http://tinyurl.com/b634l

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Work about to start on biotech center

Work about to start on biotech center

Work about to start on biotech center

Biotech News

Kerry Fehr-Snyder and Craig Harris
The Arizona Republic
Dec. 13, 2005 12:00 AM

Arizona's quest to become a biotech research powerhouse will take a big step forward next week when construction begins on a long-awaited biosciences building in downtown Phoenix.

The $29.4 million Arizona Biomedical Collaborative building, which will house research labs and equipment, has been on the drawing board for more than three years. It is a joint effort by the University of Arizona and Arizona State University, which also are collaborating on a nearby medical school.

Faculty associated with the medical college will be housed at the ABC building, said Jaime Molera, a consultant for the Arizona Board of Regents, which operates the state's three universities. advertisement

"What's going to happen is that all of the teaching space is going to be taking place in the college of medicine buildings," he said. The ABC building will house wet labs, biomedical informatics equipment and other specialty gear for research into cancer, diabetes, asthma and such neurological diseases as Alzheimer's.

Arizona Biotech
Arizona Entrepreneurs
Arizona High Tech
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Oncolytics Biotech Inc. Announces CAN$16.48 Million Private Placement

Oncolytics Biotech Inc. Announces CAN$16.48 Million Private Placement

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has entered into a private placement with a number of institutional investors. Under the agreement, Oncolytics will issue 3,200,000 units (the "Units") at a price of CAN$5.15 per Unit, resulting in gross proceeds to the Company of CAN$16,480,000. Each Unit consists of one common share and one-half of one common share purchase warrant, with each whole common share purchase warrant entitling the holder to acquire one common share upon payment of CAN$6.15 per share for a period of 36 months following the closing date. The net proceeds from the offering will be used to support the initiation of the company's Phase II clinical program and for general corporate purposes. The offering is expected to close on or about December 29, 2005 and is subject to the receipt of all necessary regulatory and stock exchange approvals.

"The funds from this financing are expected to be used to expand the clinical trial program for REOLYSIN(R) in 2006 and 2007," said Dr. Brad Thompson, President and CEO of Oncolytics. "Based on indications of activity in our ongoing U.K. Phase I systemic trial, previous clinical trials, and preclinical examination of REOLYSIN(R) in combination with several chemotherapeutic agents, our Phase II clinical trial program will potentially include combination chemotherapy/REOLYSIN(R) trials in colorectal, prostate, pancreatic and non-small cell lung cancer, and combination radiation/ REOLYSIN(R) trials in a number of tumour types."

The securities to be issued by Oncolytics have not and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or the securities laws of any state of the United States, and may not be offered or sold in the United States absent registration or an applicable exemption therefrom under the 1933 Act and the securities laws of all applicable states. This press release is not an offer of securities in the United States.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of REOLYSIN(R), its proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics' researchers have demonstrated that the reovirus is able to selectively kill cancer cells and, in vitro, kill human cancer cells that are derived from many types of cancer including breast, bladder, prostate, pancreatic and brain tumours, and have also demonstrated successful cancer treatment results in a number of animal models. Previous Phase I clinical trial results have indicated that REOLYSIN(R) was well tolerated and that the reovirus demonstrated activity in tumours injected with REOLYSIN(R).

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the placement of the units, as to progress in the clinical trial program and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, ability of the Company to complete the private placement on the terms set forth in its agreements, the use of proceeds, the Company's ability to obtain regulatory approval for the offering, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.

Arizona Biotech News
Arizona Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Monday, December 12, 2005

[ biotech news ] Bionovo to Present at 9th Annual New York Society of Security Analysts Biotech

Bionovo to Present at 9th Annual New York Society of Security
Analysts Biotech/Specialty Pharma Conference

EMERYVILLE, Calif., Dec. 12 -- Bionovo, Inc.
(OTC Bulletin Board: BNVI) announced today that Isaac Cohen, the
company's
chairman and chief executive officer, is scheduled to present at the
New York
Society of Security Analysts 9th Annual Biotech Specialty Pharma
Conference on
Wednesday December 14, at 1:40 p.m. The conference will be held at
The Harvard
Club, 27 West 44th Street, NYC.

Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery
of novel
pharmaceutical agents for cancer and women's health. The company has
two drugs
ready to enter Phase 2 clinical testing, one for breast cancer
therapy and
another to treat conditions associated with menopause. The company is
developing its products in close collaboration with leading U.S.
academic
research centers including the University of California, San
Francisco;
University of Colorado Health Sciences Center; University of
California,
Berkeley; and University of Texas, Southwestern. For further
information
please visit: www.bionovo.com.

Forward-looking Statements
This release contains certain forward-looking statements
relating to the
business of Bionovo, Inc. that can be identified by the use of
forward-looking
terminology such as "believes," "expects," or similar expressions.
Such
forward-looking statements involve known and unknown risks and
uncertainties,
including uncertainties relating to product development, efficacy
and safety,
regulatory actions or delays, the ability to obtain or maintain
patent or
other proprietary intellectual property protection, market
acceptance,
physician acceptance, third-party reimbursement, future capital
requirements,
competition in general and other factors that may cause actual
results to be
materially different from those described herein as anticipated,
believed,
estimated, or expected. Certain of these risks and uncertainties are
or will
be described in greater detail in our filings with the Securities
and Exchange
Commission SEC), which are available at www.sec.gov. Bionovo, Inc.
is under no
obligation (and expressly disclaims any such obligation) to update
or alter
its forward-looking statements whether as a result of new
information, future
events or otherwise.

SOURCE Bionovo, Inc.
Web Site: www.bionovo.com

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.imhcaz.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

GPC Biotech starts phase II trial on Satraplatin to treat lung cancer - Forbes.com

GPC Biotech starts phase II trial on Satraplatin to treat lung cancer - Forbes.com

GPC Biotech starts phase II trial on Satraplatin to treat lung cancer
12.09.2005, 04:28 AM

Cancer Treatment

MARTINSRIED, Germany (AFX) - GPC Biotech AG said it has started a phase II trial to evaluate the Satraplatin drug, in combination with Taxol, as first-line therapy in patients with advanced non-small cell lung cancer that cannot be surgically removed.

The primary objective of this study -- which is expected to enrol up to 40 patients -- is to determine the response rate of Satraplatin in combination with Taxol.

It will also examine time to progression and overall survival rates.

The drug is currently in a Phase III trial for patients with hormone-refractory prostate cancer who have already undergone and failed one previous treatment.

The company is also opening new clinical studies to explore the potential of Satraplatin in a number of additional tumour types.

Arizona Biotech
Arizona Biotech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Two Leading Biotech Publications Report on Advaxis' Potential Treatment

Two Leading Biotech Publications Report on Advaxis' Potential
Treatment for Cervical Cancer

PRINCETON, N.J. Dec 12, 2005 - Two leading biotech publications
reported that Advaxis, Inc. (ADXS.OB) successfully demonstrated in
testing of mice at the University of Pennslyvania that a live
listeria vaccine can eradicate existing, rapidly-growing breast
tissue tumors.

Genetic Engineering News, in its December 8th issue, reported that
Dr. Yvonne Paterson, professor of microbiology at the University of
Pennsylvania, and chair person of Advaxis' Scientific Advisory
Board, presented a study in a recent issue of the Journal of
Immunology that ten years of scientific research produced evidence
of the cancer-fighting properties of a live modified listeria cancer
vaccine she created.

Dr. Paterson's research indicates that listeria activates the body's
cytotoxic T cells to help the immune system take a stronger stance
in the presence of cancer cells, Genetic Engineering News reported.

"If Lovaxin C is successful in clinical trials it has the potential
for <a href="http://www.imhcaz.com/" >treating cervical cancer</a>
in early and late stage disease, including those women who have
positive pap smears and currently require surgery," explained John
Rothman, Advaxis'vice president of clinical development.

DrugResearcher.com, reported in its December 6th issue that Advaxis'
Lovaxin C, a proprietary listeria vaccine, "could soon be on the
horizon after researchers took a giant step in development of
effective cancer-fighting vaccines that appear to be able to stop
and reverse cancer growth."

"The newly developed vaccine therapies for cervical cancer are
directed at those women who have not been exposed to HPV, the viral
cause of cervical cancer," DrugResearcher.com reported. "Lovaxin C,
which will be entering a Phase I/II clinical trial, is intended to
cure women who already have cervical cancer as a result of HPV
exposure."

The two articles can be found at:

www.drugresearcher.com/news/ng.asp?n=64376-advaxis-listeria -cancer
and www.genengnews.com/stickyends/article.aspx?sid=149. (Due to the
length of this URL, it may be necessary to copy and paste this
hyperlink into your Internet browser's URL address field.)

About Advaxis

Based in Princeton, New Jersey. Advaxis is developing proprietary
Listeria cancer vaccines based on technology developed by Dr. Yvonne
Paterson, professor of microbiology at the University of
Pennsylvania, and chair person of Advaxis' Scientific Advisory
Board.. Advaxis' is developing therapeutic cancer vaccines that
enhance the immune system's cancer-fighting abilities through its
proprietary Listeria monocytogenes based system, which utilizes two
immunological mechanisms (Innate and Classical Immunity) to develop
safer and more effective Listeria based cancer vaccines. Advaxis is
the exclusive licensee of a patented broadly enabling Listeria
platform technology that can elicit effective anti-tumor responses.
Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets
cervical and head and neck cancers. Further Listeria vaccines in
development target breast, ovarian and lung cancers. Advaxis is
entering a Phase I/II clinical trial in late 2005. The Listeria
platform will also have applications in the fields of infectious
disease and autoimmune disorders.

Forward-Looking Statements

Certain statements contained in this press release are forward-
looking statements that involve risks and uncertainties. The
statements contained herein that are not purely historical are
forward looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements deal
with the Company's current plans, intentions, beliefs and
expectations and statements of future economic performance. Forward-
looking statements involve known and unknown risks and uncertainties
that may cause the Company's actual results in future periods to
differ materially from what is currently anticipated. Factors that
could cause or contribute to such differences include those
discussed from time to time in reports filed by the Company with the
Securities and Exchange Commission. The Company cannot guarantee its
future results, levels of activity, performance or achievements.

http://www.imhcaz.com/
http://www.azhttp.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Tanox ready for Chang change

Tanox ready for Chang change
Biotech firm co-founder will hand over CEO reins after 20 years

By Mary Ann Azevedo
Houston Business Journal
Updated: 7:00 p.m. ET Dec. 11, 2005

Nancy Chang has called the shots at Tanox Inc. for 20 years.

Now the co-founder of the publicly held biopharmaceuticals company is stepping aside as president and CEO to assume duties as chairman of the board.

Effective Feb. 1, 2006, Chang will replace current board Chairman Osama Mikhail, who will be lead director at Houston-based Tanox.

Chang has guided Tanox through an eventful two decades since founding the company in 1986 to develop therapies for the treatment of immune-mediated diseases, inflammation, infectious diseases and cancer.

Tanox ready for Chang change - Houston - MSNBC.com

Cancer Treatments
AZhttp
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Nanogen Releases Two Products for the Detection of Respiratory Viral Pathogens

Nanogen Releases Two Products for the Detection of Respiratory Viral
Pathogens

SAN DIEGO, Dec. 12 -- Nanogen, Inc. (Nasdaq: NGEN - News),
developer of advanced diagnostic products, announced today it has
expanded its molecular reagent product portfolio to include two new
products to detect sequences for respiratory viral pathogens: a
multiplex solid-phase hybridization set of reagents that can be
employed to develop and validate assays for the detection of the
sequences of six human respiratory viruses prevalent during flu
season, and a research-use-only (RUO) real-time PCR probe and primer
set for the identification of the influenza A and B viruses.

The NGEN(TM) RVA analyte specific reagent (ASR) product can be used
to develop and validate assays to detect the sequences of and
differentiates among influenza A and B, respiratory syncytial virus
and parainfluenza 1, 2 and 3. Assays validated using NGEN(TM) RVA
ASR can be carried out with various sample types, including nasal
swabs and, once validated by the laboratory, can be used as a
clinical diagnostic test. The product was developed in cooperation
with Prodesse, Inc., a leading supplier of molecular-based reagents
for infectious disease targets, and is available in the United
States as an ASR for which analytical and performance
characteristics are not established. The product has been CE marked
in the European Union as an in vitro diagnostic and is available
outside the United States.

Additionally, Nanogen has expanded its real-time PCR product group
with an RUO probe and primer set for the identification of the
influenza A and B viruses. The MGB Eclipse® Flu A/B RUO product uses
the company's proprietary MGB(TM) technology to provide melt curve
analysis that differentiates the two viral strains for each sample.
The new MGB Eclipse® Flu A/B primer and probe set, along with the
recently released Enterovirus and hMPV reagents, complement
Nanogen's growing MGB Alert(TM) product family of ASRs targeting
infectious agents, such as herpes viruses and pneumonias.

Both sets and reagents target a nucleic acid sequence also found in
the H5N1 strain of the influenza A virus, also known as avian flu.
Laboratories interested in screening for avian flu can choose
between the real-time PCR research reagents or the set of ASRs that
can be validated for clinical use. Positives could then be sequenced
for epidemiological studies.

"The market for respiratory virus testing is estimated to be over
$100 million annually. With the shipment of these new products,
Nanogen is making a strong play to grab a piece of that market,"
noted Howard C. Birndorf, chairman and chief executive officer of
Nanogen. "Traditionally, labs testing for flu have been limited to
choosing between simple rapid tests, which often lack sensitivity
and specificity, or culture-based tests that are slow to get
results. Our advanced molecular-based technologies offer clinical
and research labs additional options. We believe our products will
enable changes in laboratory procedures that can influence better
prescribing practices and improve patient care."

About Nanogen, Inc.

Nanogen's advanced technologies provide researchers, clinicians and
physicians worldwide with improved methods and tools to predict,
diagnose, and ultimately help treat disease. The company's products
include real-time PCR reagents, the NanoChip® electronic microarray
platform and a line of reagents useful in rapid diagnostic tests.
Nanogen's ten years of pioneering research involving nanotechnology
holds the promise of miniaturization and continues to be supported
for its potential for diagnostic and biowarfare applications. For
additional information please visit Nanogen's website at
www.nanogen.com.

Forward-Looking Statement

This press release contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results
to differ materially from those set forth in the forward-looking
statements, including whether products under development can be
successfully developed and commercialized, whether patents owned or
licensed by Nanogen will be developed into products, whether the
patents owned by Nanogen offer any protection against competitors
with competing technologies, whether results reported by our
customers or partners can be identically replicated, and other risks
and uncertainties discussed under the caption "Factors That May
Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q
most recently filed with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof.
Nanogen disclaims any intent or obligation to update these forward-
looking statements.

---------------------------------------------------------------------
-----------
Source: Nanogen, Inc.

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.imhcaz.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Biotech courses most popular

Biotech courses most popular
Anil Prabha

KUALA LUMPUR, Sun.
--------------------------------------------------------------------------------

Biotechnology and biomedicine are the most popular courses after medicine among Malaysians seeking to study in the National University of Singapore.
Business and engineering courses were also among their top choices, said NUS admissions officer Juliet Ho at the Facon Education Fair today.

That accorded with the experience of other universities’ recruitment officers and the fair’s organisers.

School-leavers at the fair were applying for degrees in medicine, biotechnology and biomedical sciences, said Stephanie Hah, senior marketing manager of Monash University.

New Straits Times - Malaysia News Online

AZhttp
Cancer Treatment
Biotech
Biotech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Friday, December 09, 2005

Sinovac gets funding for bird flu vaccine

Sinovac gets funding for flu vaccine

The Associated Press/NEW YORK

Sinovac gets funding for bird flu vaccine

Sinovac gets funding for flu vaccine

DEC. 9 11:33 A.M. ET Beijing-based vaccine developer Sinovac Biotech Ltd. said Friday it received 7 million yuan ($867,000) from China's Ministry of Science and Technology for preclinical trials of its proprietary pandemic flu vaccine, Panflu.

Sinovac said it has received more than $1 million from the Chinese government since April 2004 to develop the bird flu vaccine. The company said the vaccine includes aluminum to boost immune response, which allows for smaller doses -- making it possible to produce more doses quickly and respond to a possible bird flu pandemic.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Pelias AG - New Biotech Startup to Fight Hospital Infections

Pelias AG - New Biotech Startup to Fight Hospital Infections

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/

VIENNA, Austria, December 9

- Pelias AG Announced Today the Start of its Operations.
Headquartered at the Campus Vienna Biocenter in Vienna, Pelias Will
Focus on the Development of Novel Products for the Prevention and
Treatment of Hospital-acquired Infections, Usually Called Nosocomial
Infections.

Foundation

The foundation of Pelias is based on a strong global partnership
between Intercell and Parteurop, who joined forces to build up a new
biotech company by combining their expertise, technologies and
product candidates. The start up is seed financed primarily through
Intercell and an atypical silent partnership of Kapital & Wert. The
company will also seek to obtain public subsidies. With licensed
technologies from Chiron and Intercell, Pelias' mission is to
develop novel vaccines and antibody-based therapies for the
prevention and treatment of hospital-acquired infections. The
company's lead product is a novel vaccine licensed from Chiron
against Pseudomonas infection, which has already been in clinical
trials.

Nosocomial infections are one of the major causes of death and
serious illness worldwide and result in annual burden of US$20Bn in
the developed world.

"An advanced product, enabling technologies, an excellent team as
well as strong financial support offered a unique opportunity to
address this area of high unmet medical need," states Gerd
Zettlmeissl, CEO Intercell AG. "Intercell will retain and emphasize
its focus on its advanced products and development pipeline while
Pelias' core competence will be the development of products against
nosocomial infections."

Robust product pipeline and successful technologies

Pelias has started its business with three key projects targeting
important pathogens in hospital infections: Pseudomonas,
Enterococcus and Klebsiella.

The Pseudomonas product candidate is licensed from Chiron and has
already achieved a clinical proof of concept in a Phase IIa clinical
trial. For the Enterococcus and Klebsiella projects, Pelias is using
Intercell's proven and highly successful Antigen Identification
Program to identify novel protective antigens. "These two projects
using the valuable Intercell AIP technology and our advanced product
candidate already in clinical development provide our company with
an unique and promising pipeline right from the beginning," states
Mathias Grote, CEO of Pelias.

Medical need

Pseudomonas, Enterococcus and Klebsiella are bacterial infections
acquired by people being in hospital care. The majority of them
cause a variety of disorders, notably pneumonia, urinary tract
infections and sepsis. The incidence of nosocomial infections is
steadily increasing due to a variety of reasons, most notably the
ongoing emergence of antibiotic resistant bacteria circulating in
hospitals. Due to the growing problem there is clearly a very large
unmet need to develop effective prophylactic, post exposure and
therapeutic vaccines to effectively combat nosocomial infections.
Despite this obvious urgent need, there are only a very few products
of this type currently in development within the pharmaceutical and
biotechnology industries.

Network of excellence

Founded out of a strong global partnership, Pelias combines the know-
how and expertise of leading experts in the field of infectious
diseases. Mathias Grote, former Senior Vice President of Commercial
Operations at Intercell will lead the company as CEO. Before joining
Intercell, Mathias Grote gained a broad experience in senior
management functions in development, manufacturing and business
development e.g. at Chiron Vaccines. Jacques-Francois Martin, the
former CEO of Pasteur Merieux and President of "The Vaccine Fund",
who was involved in the pharmaceutical, biological and life science
industries with a strong focus on vaccines for more than 30 years,
will chair Pelias' Supervisory Board. "I have always been fascinated
by biotech companies that strike new paths to develop innovative
treatments to overcome huge burdens in our healthcare system.
Pelias, founded by leading vaccine players, combines the excellent
know-how and expertise of a global network in his team", he states.

Together with leading clinicians, scientists and an international
cooperation network, Pelias and its dedicated team is ready to focus
on one of the most important challenges of the 21st century.

"As experienced investor in life sciences we were convinced of
Pelias' business concept and decided to support the company from the
very beginning," states Michael Stranz, Executive Board at Kapital &
Wert.

Key shareholders

Key shareholders include Intercell, Go Equity, Chiron, Parteurop,
Bioalliance and the Management.

About nosocomial infections

Nosocomial infections are bacterial or fungal infections which are
acquired in a hospital setting and cause a variety of severe
infections, many life-threatening such as pneumonia, sepsis and
bacteremia. 2 million infections occur every year and 100,000 annual
deaths in the US alone are due to nosocomial infections. The annual
burden to the society is constantly increasing due to the
antibiotics resistance of the most problematic bacteria.

About Intercell

Intercell AG is a fast growing biotechnology company focusing on the
design and development of novel vaccines for prevention and
treatment of diseases with substantial unaddressed medical need. The
Company's unique position is based on the combination of antigens
and immunizers (adjuvants) derived from its proprietary technology
platforms and its in-house GMP manufacturing facilities. Intercell's
technology has been endorsed by collaborative agreements with a
number of global pharmaceutical companies, including Sanofi Pasteur,
Merck&Co. Inc., SciGen Ltd. and the Statens Serum Institut. The
Company has a broad development pipeline with a vaccine for Japanese
Encephalitis in Phase III, a vaccine for Hepatitis C in Phase II, a
partnered Tuberculosis vaccine in Phase I and five products focused
on infectious diseases in pre-clinical development. Intercell is
listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: www.intercell.com

About Kapital & Wert

Kapital & Wert has been established since 1981, has 49 employees and
36,500 customers. Up until now, there have been 56 investments made,
e.g. Zellstoff Pöls AG, Steyrermühl AG, Cosmos, Ankerbrot,
Intercell, Familia-Märkte, Dogro Warenhandel, Vogel & Noot
Landmaschinenfabrik AG, FSG Biosupport Forschungs GmbH, BV
Biotechnologies GmbH, IMS Nanofabrication GmbH. Another 31
precaution real estate funds and 10 closed real estate funds
projects were planned and executed.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Coalition of Biotech, High-Tech Industries Seeks to Protect Small Businesses

Coalition of Biotech, High-Tech Industries Seeks to Protect Small
Businesses Through Sarbanes-Oxley Regulatory Reform

SEC Advisory Committee Accepting Comments on
Reforming Corporate Governance Act

WASHINGTON, Dec. 8 -- The Biotechnology Industry Organization
(BIO) and a coalition of biotechnology, healthcare technology, high-
technology
and venture capital industries today submitted a letter to an SEC
advisory
committee requesting reform to Section 404 (internal controls) of the
Sarbanes-Oxley Act of 2002.
"We're not proposing to change a single word of the Sarbanes-
Oxley
legislation. But, complying with the Sarbanes-Oxley external auditor
requirement can cost upwards of $1 million, often doubling a small
firm's
operating costs," said Jim Greenwood, BIO's president and
CEO. "Unintended
consequences of the cost burdens associated with a 'one-size-fits-
all'
approach to Section 404 continues to hamper small companies' ability
to invest
in research and development and to gain access to public capital
markets."
The coalition wants the Securities and Exchange Commission (SEC)
to ease
disproportionate financial burdens on small public companies.
Sarbanes-Oxley,
the corporate governance law, requires publicly traded companies to
adhere to
standards that broaden board members' roles in overseeing financial
transactions and auditing procedures.
Coalition members working with BIO include the National Venture
Capital
Association, TechNet, Advanced Medical Technology Association,
California
Healthcare Institute and SEMI. The coalition represents more than
5,300
companies from 50 states and around the world.
"We do not oppose government oversight, rather, we want to
ensure that
oversight is conducted in a manner that is fair to small biotech or
high-tech
businesses. Some of these cost burdens threaten to jeopardize the
competitiveness of smaller companies that are the growth engines of
the U.S.
economy," said Morrie Ruffin, BIO's executive vice president of
capital
formation and business development.
The SEC formed the Advisory Committee on Smaller Public
Companies to
consider ways of improving the impact of Sarbanes-Oxley on small
public
companies. The committee has been holding public hearings to seek
recommendations from stakeholders and will meet Wednesday, Dec. 14,
2005 to
review those recommendations and prepare draft proposals for the
SEC. The
meeting will be held in Multi-Purpose Room L006 of the SEC's
headquarters,
located at 100 F Street, NE, Washington DC, 20549.
The coalition recommends that smaller public companies be:

* Defined as the bottom 6 percent (based on a quarterly average)
of the
total U.S. public market capitalization or by a revenue
threshold set by

the average revenues of companies at the bottom 6 percent of
total
market capitalization;

* Exempt from having external auditors attest to internal
controls. This
would not exempt small public companies from complying with
Sarbanes-
Oxley as a whole.

* Allowed to take a risk-based approach to prioritizing their key
financial controls and be allowed to alternate the frequency
of control
testing to every second or third year.

A copy of the letter can be viewed by clicking on
www.bio.org/tax/issues/LettertoSEC.pdf.

BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the
United States and 31 other nations. BIO members are involved in the
research
and development of healthcare, agricultural, industrial and
environmental
biotechnology products.

SOURCE Biotechnology Industry Organization
Web Site: www.bio.org

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Buffalo News - Skolnick resigning UB biotech center post

Buffalo News - Skolnick resigning UB biotech center post

Skolnick resigning UB biotech center post

Arizona Biotech
Biotech News

--------------------------------------------------------------------------------
Bioinformatics expert lands job in Georgia

By STEPHEN T. WATSON
News Staff Reporter
12/9/2005

Click to view larger picture

Jeffrey Skolnick is leaving Jan. 10 for a job in Georgia.

Jeffrey Skolnick, the prominent scientist hailed as the "rock star" of bioinformatics research when he arrived at the University at Buffalo in 2002, is leaving UB for a job at the Georgia Institute of Technology.
Skolnick has submitted a resignation letter, effective Jan. 10, and will take a position as director of a center focusing on systems-biology research.

This brings an end to Skolnick's rocky term at the UB bioinformatics center, which received more than $200 million in financial support and generated high expectations as an economic engine. "His tenure's been disappointing in the sense that [he] was trumpeted as a rock star, and there weren't many concerts to attend," said Assembly Majority Leader Paul A. Tokasz, D-Cheektowaga.

Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] BioTech Medics 1st Year Anniversary Report

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/

BioTech Medics 1st Year Anniversary Report

DALLAS, Dec. 9 -- Keith Houser, CEO of BioTech
Medics, Inc., (OTC Pink Sheets: BTMD) issued a statement chronicling
the accomplishments during the first year anniversary of the
reverse/merger between Corbel Holdings, Inc., and HaloLaser
BioTherapy, LLC.

"During the past year BTMD has accomplished much," said Mr.
Houser. "We closed on the reverse/merger on time. The previous
directors and officers were replaced immediately. Under new
management and a new board of directors we hired a CPA firm to start
an audit of the merged companies. The auditors have completed IRS
filings through 2004, but not completed the audit. We pledged 'no
reverse stock split' and we have kept our word.

"BioTech Medics has acquired over $2.5 million in assets this
year (with cash and treasury stock) and has a steady revenue income
in the management agreement with Charles R. Crane MD & Associates in
forming our first Pain Management & Wellness Center in Dallas,
Texas. Additionally BTMD acquired 5 US Letters of Patent from FHJ
and have started marketing the proprietary SHBAN Cleaning &
Disinfecting Solution. BTMD entered into a distributorship
agreement with Laser Neurotherapy Development Labs and have sold the
NeuroLase Medical Laser device to clinics in the USA. We negotiated
turnkey financing for the laser acquisitions through First Financial
Leasing & Financing.

Mr. Houser stated: "In 2004 Corbel had under $500,000 in Real
Estate
Assets. Since the reverse/merger BTMD has had a 400% increase in non-
real
estate Assets. BTMD estimates to close 2005 with combined Gross
Revenues
around $ 1 million. The 2005 BTMD revenues are projected to be
nearly 20 times
higher than 2004.
"BTMD plans on closing on more new Pain Management & Wellness
Centers in
2006, as well as acquiring a permanent office building in Dallas,
Texas. We
pledge to strive to add more assets and increased revenue for the
company to
bring more value to the stock and its more than 5,800 shareholders
in 22
countries. This in turn should provide BTMD the opportunity to
become a
reporting company and the possibility to move up to a major
exchange."

For More Information Contact BioTech Medics at 972-274-5533 or
on the
Internet at: www.biotechmedics.com

Safe Harbor for Forward-Looking Statements
This press contains forward-looking statements within the
meaning of The
Private Securities Litigation Reform Act of 1995 (the "Act"). In
Particular,
when used in the preceding discussion, the words "plan," "expect,"
or "intend
to," and similar conditional expressions are intended to identify
forward-
looking statements within the meaning of the Act. Such statements
are subject
to certain risks and uncertainties and actual results could differ
materially
from those expressed. Such risks and uncertainties include, but are
not
limited to, the ability of the company to have adequate financing,
market
conditions, the general acceptance of the Company's products and
technologies,
competitive factors, timing, and other risks.

CONTACT: BioTech Medics, Inc., +1-972-274-5533

SOURCE BioTech Medics, Inc.
Web Site: www.biotechmedics.com

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] GPC Biotech Announces Start of Phase 2 Trial Evaluating Satraplatin Plus Taxol(R

GPC Biotech Announces Start of Phase 2 Trial Evaluating Satraplatin
Plus Taxol(R) in Patients With Advanced Non-Small Cell Lung Cancer

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/

MARTINSRIED/MUNICH, GERMANY -- 12/09/2005 -- Waltham, Mass. and
Princeton, N.J. -- GPC Biotech AG (Frankfurt: GPC) (TecDAX Index)
(NASDAQ: GPCB) today announced that a Phase 2 study evaluating the
Company's lead drug candidate, satraplatin, in combination with
Taxol® (paclitaxel) as a first-line therapy in patients with
unresectable advanced non-small cell lung cancer (NSCLC) has opened
for accrual. Satraplatin is currently in a Phase 3 registrational
trial as a second-line chemotherapy treatment for patients with
hormone-refractory prostate cancer. The Company is also opening new
clinical studies to explore the potential of satraplatin in a number
of additional tumor types.

The Phase 2 study in advanced NSCLC is an open label study being led
by investigators at the Sarah Cannon Research Institute (SCRI) in
Nashville, Tennessee. The study will also be open for accrual in
their affiliated network of oncologists, Tennessee Oncology. The
primary objective of this study is to determine the objective
response rate of satraplatin in combination with Taxol in this
patient population. The study will also examine time to progression
and overall survival. The study is expected to enroll up to 40
patients.

"I look forward to further exploring the potential of satraplatin
with Taxol in the advanced lung cancer setting, as this new study
builds on the Phase 1 study my team did with this combination," said
F. Anthony Greco, M.D., Medical Director, SCRI. "Platinum-based
therapies are widely used to treat patients with advanced non-small
cell lung cancer. Satraplatin, as an oral platinum-based compound
that is well tolerated, could, if effective, be an important new
option for treating patients with this disease."

"SCRI is a renowned research support services organization that
works in concert with the Sarah Cannon Cancer Center, the largest,
privately-funded, community-based cancer treatment program in the
U.S. Dr. Greco is a distinguished medical oncologist there who has
been instrumental in developing new and improved therapies for
cancer," said Marcel Rozencweig, M.D., Senior Vice President, Drug
Development of GPC Biotech. "The opening of this trial continues our
strategy of initiating studies at highly regarded cancer centers to
explore the potential of satraplatin in combination with other
anticancer therapies and for the treatment of other cancers beyond
the initial indication for second-line chemotherapy of hormone-
refractory prostate cancer."

Lung cancer is the leading cause of cancer death in the U.S., with
an estimated 163,000 deaths expected from the disease in 2005. Over
170,000 new cases are expected to be diagnosed in 2005. The five-
year survival rate for lung cancer in the U.S. is only 15 percent.
Recent statistics for Europe estimated over 375,000 cases annually
of lung cancer and over 345,000 deaths from the disease. NSCLC
accounts for over 80 percent of all lung cancer cases.

About Satraplatin

Satraplatin, an investigational drug, is a member of the platinum
family of compounds. Over the past two decades, platinum-based drugs
have become a critical part of modern chemotherapy treatments and
are used to treat a wide variety of cancers. Worldwide sales of
these drugs exceeded $2.2 billion in 2004. Unlike the platinum drugs
currently on the market, all of which require intravenous
administration, satraplatin is an orally bioavailable compound and
is given as capsules that patients can take at home. An oral
platinum drug could offer key advantages, including ease of
administration and patient convenience, in a variety of
applications. Satraplatin is in a Phase 3 registrational trial --
the SPARC trial -- as a second-line chemotherapy treatment for
hormone-refractory prostate cancer (HRPC). GPC Biotech has completed
a Special Protocol Assessment with the U.S. FDA and has received a
Scientific Advice letter from the European regulatory authority, the
European Medicines Agency (EMEA). The FDA has also granted fast
track designation to satraplatin for this indication. Satraplatin
was in-licensed from Spectrum Pharmaceuticals, Inc.

Phase 2 trials have been completed in HRPC, ovarian cancer and small-
cell lung cancer. Promising early clinical results have also been
shown when satraplatin is combined with radiation therapy, and a
Phase 1/2 study evaluating this combination in patients with non-
small cell lung cancer has been initiated. Several others studies
evaluating satraplatin in combination with other therapies and in
various cancers are underway or planned. Further information on
satraplatin can be found in the Anticancer Programs section of the
Company's Web site at www.gpc-biotech.com.

About Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI), a company created by HCA and
Tennessee Oncology, is dedicated to advancing solutions for a
healthier tomorrow through clinical research. It is one of the
largest, community-based research support programs offering
management, regulatory and other research support services for
strategic investigator sites across the country in ten therapeutic
areas. SCRI works to provide greater access to oncology-related
clinical trials in a community setting through a powerful network of
500 oncologists in 25 states.

About GPC Biotech

GPC Biotech AG is a biopharmaceutical company discovering and
developing new anticancer drugs. The Company's lead product
candidate -- satraplatin - - is currently in a Phase 3
registrational trial as a second-line chemotherapy treatment in
hormone-refractory prostate cancer following completion of a Special
Protocol Assessment by the U.S. FDA and receipt of a Scientific
Advice letter from the European central regulatory authority, EMEA.
The FDA has also granted fast track designation to satraplatin for
this indication. Other anticancer programs include: a monoclonal
antibody with a novel mechanism-of-action against a variety of
lymphoid tumors, currently in Phase 1 clinical development, and a
small molecule broad-spectrum cell cycle inhibitors program,
currently in pre-clinical development. The Company also has a number
of drug discovery programs that leverage its expertise in kinase
inhibitors. GPC Biotech has a multi-year alliance with ALTANA Pharma
AG working with the ALTANA Research Institute in the U.S., which
provides GPC Biotech with revenues through mid-2007. GPC Biotech AG
is headquartered in Martinsried/Munich (Germany). The Company's
wholly owned U.S. subsidiary has research and development sites in
Waltham, Massachusetts and Princeton, New Jersey. For additional
information, please visit the Company's Web site at www.gpc-
biotech.com.

This press release may contain projections or estimates relating to
plans and objectives relating to our future operations, products, or
services; future financial results; or assumptions underlying or
relating to any such statements; each of which constitutes a forward-
looking statement subject to risks and uncertainties, many of which
are beyond our control. Actual results could differ materially
depending on a number of factors, including the timing and effects
of regulatory actions, the results of clinical trials, the Company's
relative success developing and gaining market acceptance for any
new products, and the effectiveness of patent protection. There can
be no guarantee that the SPARC trial will be completed nor that
satraplatin will be approved for marketing in a timely manner, if at
all. In addition, there can be no guarantee regarding the results of
the satraplatin Phase 2 study in combination with paclitaxel in
patients with advanced non-small cell lung cancer. We direct you to
the Company's Annual Report on Form 20-F, as amended, for the fiscal
year ended December 31, 2004 and other reports filed with the U.S.
Securities and Exchange Commission for additional details on the
important factors that may affect the Company's future results,
performance and achievements. The Company disclaims any intent or
obligation to update these forward-looking statements or the factors
that may affect the Company's future results, performance or
achievements, even if new information becomes available in the
future.

Taxol® (paclitaxel) is a registered trademark of Bristol-Myers
Squibb Company.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Wednesday, December 07, 2005

[ biotech news ] TGen Interns Take First Place in Prestigious Science Competition

TGen Interns Take First Place in Prestigious Science Competition

Winners receive $100,000, ring Stock Market's closing bell

12-05-2005

New York, NY, December 5, 2005-The Translational Genomics Research
Institute (TGen) today announced that two graduates of the
Institute's summer internship program took the top prize at the
nation's premier high school science competition, the Siemens
Westinghouse Competition in Math, Science and Technology.
Anne Lee, a senior at Phoenix Country Day School in Paradise Valley,
and Albert Shieh, a junior at Chaparral High School in Scottsdale,
won the $100,000 prize in the team category, which they will share
equally, for developing new software that more accurately analyzes
genetic data. In addition to the prize, the winners will ring the
closing bell at the New York Stock Exchange today.

TGen summer interns Albert Shieh, a junior at Chaparral High School
in Scottsdale, and Anne Lee, a senior at Phoenix Country Day School
in Paradise Valley, took first place in the team category at the
2005-2006 Siemens Westinghouse Competition in Math, Science and
Technology. The winners were announced this morning at New York
University, host of the Siemens Westinghouse Competition National
Finals.

"We worked really hard all summer on the project," said Shieh. "It
was such an honor that our project was chosen." Lee agrees. "I am so
excited. We couldn't have done this without TGen and our mentors
there," she said.

The Siemens Westinghouse Competition was launched in 1998 to
recognize America's best and brightest students in math, science and
technology. This year, 1,684 students entered the competition, a 13%
increase over the previous year.

"Anne and Albert have received one of the top honors for all science
students," said Dr. Jeffrey Trent, president and scientific director
at TGen. "The fact that these outstanding young scientists are from
Arizona and were mentored here at TGen is something we are all
extremely proud of."

Lee and Shieh received the team prize for developing an improved
software package that analyzes genetic data. The team developed
their project, titled SNiPer: Improved SNP Genotype Calling for
Affymetrix 10K GeneChip Microarray Data, under the mentorship of
TGen's Drs. Dietrich Stephan, David Craig and Matt Huentelman.

"It is amazing to think of the accomplishments of these two high
school students," said Dr. Craig. "Between the two of them, they
have already published three major scientific articles."

The students' research was published in the October 31, 2005, issue
of the genetics journal, BMC Genomics.

During their summer internship at TGen, the students identified an
opportunity to improve on a commercially developed software package
designed to analyze high volume genetic data. They developed
improved genetic analysis softwarewhich TGen now usesthat enables
more accurate and efficient identification of the genes underlying
inherited disorders in humans. The team then used their software to
pinpoint a mutated gene that causes a childhood degenerative
disorder.

"Anne and Albert's software tools will positively impact
investigators worldwide," said Dr. Huentelman. "We could not be
happier to see these young researchers win this prestigious
competition."

The Siemens Westinghouse Competition finals were judged by a panel
of prominent scientists and mathematicians headed by lead judge Dr.
Constance Atwell, consultant and former Director for Extramural
Research, National Institute of Neurological Disorders and Stroke at
The National Institutes of Health. Nineteen students competed in the
National Finals, including six individuals and six teams. The
national finalists previously competed in a series of regional
competitions held at six leading research universities over three
consecutive weekends in November.

# # #

Media Contact:
Amy Erickson-TGen (602) 343-8522

About TGen
The mission of the Translational Genomics Research Institute (TGen)
is to make and translate genomic discoveries into advances in human
health. Translational genomics research is a relatively new field
employing innovative advances arising from the Human Genome Project
and applying them to the development of diagnostics, prognostics and
therapies for cancer, neurological disorders, diabetes and other
complex diseases. TGen is focused on personalized medicine and plans
to accomplish its goals through robust and disease-focused research.

About The Siemens Foundation
Established in 1998, the Siemens Foundation provides nearly $2
million in college scholarships and awards each year for talented
high school students in the United States. Based in Iselin, New
Jersey, the Foundation's signature programs -- the Siemens
Westinghouse Competition in Math, Science & Technology, the Siemens
Awards for Advanced Placement, and the Siemens Teacher Scholarships -
- recognize exceptional achievement in science, math and technology.
By supporting outstanding students today, and recognizing the
teachers and schools that inspire their excellence, the Foundation
helps nurture tomorrow's scientists and engineers. The Foundation's
mission is based on the culture of innovation, research and
educational support that is the hallmark of Siemens' U.S. operating
companies and its parent company, Siemens AG. For more information,
visit http://www.siemens-foundation.org

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Genetics and Mathematics Research Win Top Honors in Siemens Westinghouse Competi

Genetics and Mathematics Research Win Top Honors in Siemens
Westinghouse Competition

Genetics and mathematics research won top honors for Michael
Viscardi and the team of Anne Lee and Albert Shieh in the 2005-06
Siemens Westinghouse Competition in Math, Science and Technology,
the nation's premier high school science competition. The Siemens
Westinghouse Competition, a signature program of the Siemens
Foundation, is administered by the College Board. The winners were
announced at New York University, host of the 2005-06 Siemens
Westinghouse Competition National Finals.

Michael Viscardi of San Diego, California is Individual Winner of
$100,000 Grand Prize; Anne Lee of Paradise Valley, AZ, and Albert
Shieh of Scottsdale, AZ, Win $100,000 Team Prize

Michael Viscardi, a senior who is home schooled, won the $100,000
Grand Prize scholarship in the individual category for mathematics
research with real-world engineering implications. Anne Lee, a
senior at Phoenix Country Day School in Paradise Valley, Arizona,
and Albert Shieh, a junior at Chaparral High School in Scottsdale,
Arizona, won the $100,000 prize in the team category, which they
will share equally, for developing new software that more accurately
analyzes genetic data. The winners rang The Closing Bell(tm) at the
New York Stock Exchange December 5.

"These students have done magnificent work that any researcher would
be proud of," said Thomas N. McCausland, chairman of the board of
the Siemens Foundation. "The fact that they are still in high school
makes their achievement all the more remarkable. Imagine what these
young scholars will accomplish as adults."

The national finals were judged by a panel of prominent scientists
and mathematicians headed by lead judge Dr. Constance Atwell,
consultant and former Director for Extramural Research, National
Institute of Neurological Disorders and Stroke at The National
Institutes of Health.

"On behalf of all the judges, I congratulate these outstanding young
scientists and mathematicians on reaching the highest level of
achievement in this extremely challenging competition," said Dr.
Atwell.

Nineteen students competed in the National Finals, including six
individuals and six teams. The national finalists previously
competed in a series of regional competitions held at six leading
research universities over three consecutive weekends in November.

http://groups.yahoo.com/group/biotech-news/
http://www.azizonabiotech.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Tuesday, December 06, 2005

[ biotech news ] Bodisen Biotech Signs US$43 Million in Contracts, Sees Record Earnings for 2006

Bodisen Biotech Signs US$43 Million in Contracts, Sees Record
Earnings for 2006 and Continued Favorable Market Environment;
Company Updates Growth Strategies for 2006

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

NEW YORK-- --Dec. 6, 2005--Bodisen Biotech, Inc. (AMEX: BBC,
website: www.bodisen.com), the first China based environmentally
friendly bio fertilizer company listed on a US stock exchange,
announced today that the company has signed a total of US$43 million
in contracts for 2006 product delivery with various new and existing
wholesale distributors during two national agricultural product
trade shows which take place annually in November in China. Bodisen
expects to fill these and new orders throughout 2006. In 2005,
Bodisen signed over $20 million in contracts in 2004 for 2005
product delivery from these trade shows. Bodisen believes the
company has existing capacity to meet these demands.

Bodisen markets its products through over 600 nationwide wholesale
distributors who then retail the products to farms and individual
farmers. From the two trade shows, Bodisen noted that more and more
Chinese farmers are identifying Bodisen products as quality and
effective for higher crop yields. Bodisen expects this positive
trend to continue.

Bodisen sees record 4th quarter earnings as well as record 2006
earnings on organic growth from existing product lines in a
favorable market environment. Bodisen continues to experience over
30% on average net income margins across almost all products lines,
which are several times higher than those of global chemical
fertilizer companies.

Bodisen provides the following information regarding recent
developments and 2006 outlook and growth strategies:

BODISEN OFFERS ENVIRONMENTALLY FRIENDLY PRODUCTS

Bodisen has proprietary technology with which it develops
environmentally friendly bio-fertilizers that are easily absorbed by
plants without the negative environmental effects of chemical
fertilizers. Over the years, soil conditions throughout China have
deteriorated due to heavy applications of chemical fertilizers.
Driven by consumer demand, farmers have become conscious of plant
quality and food safety. Bodisen notes that several global chemical
fertilizer companies have recently announced production cuts due in
part to decreased demand for their products in China. For the
Chinese market, Bodisen believes this is largely due to farmers'
shift in fertilizer preference from chemical fertilizers to
environmentally friendly bio fertilizers. Chinese farmers who use
bio fertilizers by Bodisen not only generate higher crop yields but
also are able to label their crops as organically grown "Green
Foods", which typically command much higher selling prices. Bodisen
believes its products are gaining market share rapidly in the
Chinese market at the expense of chemical fertilizer companies.
Bodisen expects this trend to continue for years to come.

BODISEN SEEKS EXPANSION IN CHINA WITH A BRANDING STRATEGY FOCUSED ON
ORGANICALLY GROWN "GREEN FOODS"

Bodisen plans to expand manufacturing and marketing efforts
throughout China's key agricultural spots primarily located in the
north east and northwest farm regions. Bodisen will expand on its
already well known brand and pursue a "Bodisen" agricultural product
branding strategy which stands for environmentally friendly, healthy
organically grown foods. The company believes this branding strategy
will further enhance product sales and profit margins.

BODISEN'S INVESTMENT INTO XILAN NATURAL GAS COMPANY SHOULD LOWER RAW
MATERIALS COSTS IN ADDITON TO A STRATEGIC INVESTMENT

Bodisen's recently announced investment in China based XiLan Natural
Gas company, the only privately owned Chinese company that owns 120
kilometers of high pressure natural gas pipeline in China, will
significantly lower raw material costs in urea, which is a major
component of our compound fertilizer products. The XiLan natural gas
company is in the process of becoming a public company. Once going
public, it may be the first privately owned Chinese natural gas
company listed in the US. Bodisen has a 13% equity ownership in
Xilan.

MANAGEMENT COMMENTS

Ms. Qiong Wang, CEO of Bodisen commented: "Bodisen is an
environmentally friendly company in a favorable market environment.
Bodisen has been a public company for almost two years. During this
time, our management team has been focused on earnings growth,
market share growth and corporate governance. Our shareholders have
taken notice of our stellar earnings growth as evidenced in growing
number of institutional funds owning our shares. China's
agricultural sector provides 900 million farm related jobs out of
the country's 1.3 billion in population. With proprietary
agricultural technology and less than half a percent of total
fertilizer market share, Bodisen faces tremendous growth
opportunities. With sound execution strategies, Bodisen is an access
to China's environmental solutions."

About Bodisen Biotech, Inc.

A Delaware company, Bodisen is headquartered in Shaanxi, China's
agricultural hub. The Bodisen brand is a highly recognized
fertilizer brand in China. Its environmentally friendly "green"
products support the mandate of the Chinese government to increase
crop yields for the purpose of decreasing China's dependency on food
imports. Among China's population of 1.3 billion, approximately 900
million are farmers whose incomes depend on their crop yields.

With over 60 products and approximately 600 (and growing) nationwide
distribution centers, Bodisen has experienced rapid growth.
Bodisen's products are based on proprietary agricultural technology
jointly developed by company scientists and university laboratories.
These products address grains, vegetables, and fruit crops and have
been proven to increase crop yields by 10% to 35% while being 100%
environmentally friendly.

BODISEN HAS WALL STREET RESEARCH COVERAGE

Wall Street firm New York Global Securities, Inc. ("NYGS",
www.newyorkglobal.com) provides research coverage for BBC. NYGS'
parent company New York Global Group (www.nyggroup.com) has a
significant China presence.

Safe Harbor Statement

This press release may contain forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based on the
current expectations or beliefs of Bodisen Biotech, Inc. management
and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements.

Biotech
Biotech
Entrepreneurs
Arizona
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Environmental and Production Benefits Drive Greater Demand for Biotech Crops

Environmental and Production Benefits Drive Greater Demand for Biotech Crops

Farmers Experience Year-on-Year Improvements From Biotech
Crops

WASHINGTON DC - As a result of increasing benefits from
biotechnology-derived (biotech) crop varieties, farmers are adopting
the technology with greater ease than ever before, according to a
new study update released by the National Center for Food and
Agricultural Policy (NCFAP).

In 2004, U.S. farmers planted biotech crops on 118 million
acres, an increase of 11 percent over the previous year. Compared
to conventional crops, biotech varieties increased food production
by 6.6 billion pounds, a 24 percent improvement from 2003, and
provided $2.3 billion in additional net returns for U.S. growers, a
21 percent increase from the previous year.

Biotech crops also reduced pesticide use by an additional 34
percent, or 15.6
million pounds. Pesticide use dropped by 15.6 million from 2003 to
2004.
"After nine years of commercialization, the benefits of biotech
crops are
self-evident, and growers are responding to better yields and greater
financial return by further increasing the number of acres planted
to these
varieties," said Jill Long Thompson, Ph.D., and Chief Executive
Officer of the
National Center for Food and Agricultural Policy. "Obviously, these
crops
have demonstrated great benefits to growers, but what we're seeing
now is the
significant extent to which these benefits increase each year."
The study examined 11 case studies of six biotech crops planted
in the
United States in 2004 -- corn, soybean, cotton, papaya, canola and
squash --
and is based on data from the U.S. Department of Agriculture's
National
Agricultural Statistics Service and surveys of crop specialists from
various
universities.
According to the study, insect-resistant crops again produced
the greatest
yield increase among the crops studied, improving food and fiber
production by
6.5 billion pounds. While insect-resistant traits increased
production,
herbicide-resistant varieties generated the greatest reduction in
production
costs by reducing the amount of pesticide needed and lowering costs
associated
with hand weeding and mechanical cultivation. Herbicide-resistant
varieties
cut costs by $1.8 billion and reduced pesticide use by 55.5 million
pounds.
Regionally, Midwestern states of Iowa, Nebraska, Indiana,
Illinois and
Minnesota experienced the greatest benefits from biotech crops.
Iowa farmers
experienced the largest increase in farm income ($266 million) and
the
greatest reduction in pesticides (9.1 million pounds annually).
Donna Winters, who grows biotech cotton, corn and soybean on her
farm in
Lake Providence, La., has personally experienced the benefits of
growing
biotech crops. Winters said adopting the technology not only helps
her
operation remain profitable, but also lessens agriculture's
environmental
footprint.
"When biotech crops were first commercialized, many farmers were
interested in trying out the new varieties, and now we're realizing
more
benefits with each year of planting," said Winters. "In my
operation, biotech
crops have improved my profitability by 5 to 10 percent because I
can spend
less money on inputs while boosting production by 10 to 15 percent.
Many
production factors vary each year, but we are able to sustain
improved
profitability and yield by using biotechnology despite those
variances. Most
importantly, planting biotech varieties promotes conservation farming
practices, which is important to me because I want my grandchildren
to
continue farming on our land."
While the economic and production benefits have been
significant, biotech
crops also make growers confident they can control weeds while
reducing the
need to plow the land. Farmers who practice "no-till" farming leave
their
soil undisturbed, thereby reducing soil erosion and pesticide
runoff. No-till
cotton acreage increased in the United States by 371 percent in
2004, while
soybean and corn no-till acres increased by 64 and 20 percent,
respectively.
"Farmers want to be good stewards of the land because it is the
source of
their livelihood," said Sujatha Sankula, Ph.D., and lead author of
the study.
"Biotech crops have helped them make great strides and adopt
conservation
tillage practices, which not only reduces erosion but also decreases
greenhouse gas emissions that result from cultivating the soil."
The study is an annual update of a 2002 report by NCFAP that
analyzes,
quantifies and documents the agronomic, economic and environmental
impacts of
biotech crops on U.S. agriculture. The complete
study, "Biotechnology-Derived
Crops Planted in 2004 - Impacts on U.S. Agriculture," is available
on the
Internet at http://www.ncfap.org .

The National Center for Food and Agricultural Policy is a
private,
nonprofit, non-advocacy research organization based in Washington,
D.C.
Established in 1984 at Resources for the Future, the center became an
independent organization in 1992. Researchers at the National Center
for Food
and Agricultural Policy conduct studies in four program areas:
biotechnology,
pesticides, U.S. farm and food policy and international trade and
development.
NCFAP receives funding from public and private institutions,
including
government agencies, philanthropic organizations, private
corporations and
others.

SOURCE National Center for Food and Agricultural Policy
Web Site: http://www.ncfap.org

Biotech
Biotech
Entrepreneurs
Arizona
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Sunday, December 04, 2005

[ biotech news ] Biotech Roars Back in November

Biotech Roars Back in November

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/

SAN FRANCISCO, Dec. 1 After two tough months for biotech,
the industry roared back with the Burrill Biotech Select Index
regaining the losses suffered during September and October, closing
up over 6% in November.
"Biotech is shaping up to have an exceptional year. With one
month to go, the 18.5% increase in the Burrill Biotech Select Index
compared with NASDAQ's
2.6% and the Dow's less than 1% gains since the beginning of the
year is an
incredible testimony to the successful industry's year," said G.
Steven
Burrill, CEO of Burrill & Company, a San Francisco based global
leader in life
sciences with principal activities in Venture Capital, Merchant
Banking and
Media. "Biotech's 'blue chip' companies such as Amgen (up 26% YTD),
Genentech
(up 77% in 2005), Vertex Pharmaceuticals Inc. (up a massive 141% so
far in
2005), and Gilead (45%) have led the way. With the major capital
market
indicators flat over the same period, this is a clear indication that
investors are putting their faith in biotech companies," added
Burrill.
"The performance of the Burrill Biotech indices is also a
reflection of
the fragile nature of the capital markets that we have seen over the
past 11
months. The Burrill Large-Cap Index is up over 24% year-to-date; on
the other
hand, while some small and medium size biotech companies have fared
well,
overall the 16% loss in value in the Burrill Small-Cap Index
demonstrates that
the market is not yet ready to share the risk that accompanies many
of these
exciting and often earlier stage companies."
Positive economic data stoked the general market conditions,
which was
buoyed by the news that the economy is recovering from the blow
delivered by
the Gulf Coast hurricanes. In addition, The Conference Board said
that falling
gasoline prices and an improved jobs outlook had lifted confidence
in November
to a reading of 98.9, up from 85.2 in October.
"This macro-environment certainly had a very positive effect on
biotech
and the Burrill Biotech Select Index gained 6% in lockstep with the
NASDAQ,
which gained about the same amount and the Dow closed November up
4.3%," added
Burrill.
"But on the company front it was a 'business as usual' month for
biotech
with no big attention grabbing headlines. The main news was on the
pharma
front was Merck's announcement of a major restructuring designed to
cut 7,000
employees or 11% of its workforce and close or sell five of its 31
manufacturing plants by the end of 2008 in the first phase of a
reorganization
strategy meant save up to $4 billion by the end of the decade. The
restructuring plans come as Merck faces the loss of patent
protection for its
blockbuster cholesterol drug Zocor in 2006, plus thousands of
lawsuits and
billions in potential liability from its recalled painkiller Vioxx."
Also in November, Pfizer Inc. (PFE) continued its torrid pace of
business
dealings with biotech by paying $40 million upfront and $734 million
in
potential milestones and royalties for access to Incyte
Corporation's (INCY)
portfolio of oral CCR2 antagonists, the most advanced of which is
currently in
Phase IIa studies in rheumatoid arthritis and insulin-resistant obese
patients.
Just as the Burrill Biotech Select Index is outperforming the
markets, the
same cannot be said for the AMEX Pharmaceutical Index (DRG), which
year-to-
date has dropped 3%.
"Big pharma is reacting to its pipeline and investor blues,"
noted
Burrill. "Drug discovery and development costs have risen
dramatically over
the years and the pipelines are drying up, and there is significant
competition from generics. With consumers clamoring for lower prices
and at
the same time, regulators increasing scrutiny, and delaying approval
(this
translates into more costs), it's not a pretty picture for big
pharma. But the
biotech industry with its robust product pipeline is benefiting from
the
pharmaceutical industry's malaise ... as witnessed by the fact that
pharma is
willing to pay highly for access to biotech's innovation," Burrill
continued.
Big biotechs are also getting into the act of snapping up
promising
targets. On the last day of the month, Genentech announced that it
had signed
a deal with privately owned British biotech company PIramed Ltd.
potentially
worth up to $230 million for the development of PI 3-kinase, an
enzyme
involved in a large number of cancers. The collaboration is
estimated to be
one of the largest preclinical deals ever signed by a UK biotech
company.

Biotech Top Dog Watch
Both Amgen and Genentech recorded positive gains in their share
prices at
7% and 6% respectively. This was enough to push both companies at
the $100
billion market cap mark. At the end of the month Amgen's market cap
was $99.9
billion with Genentech just ahead at $100.8 billion.

Genomics coming back
The Burrill Genomic Index recorded the largest gain in November
closing up
over 8%, perhaps reflecting a changing investor sentiment for
genomics and
proteomics companies. Solexa, Inc. (SLXA), for example, announced
that its
scientists had sequenced a human bacterial artificial chromosome
(BAC). Solexa
expects its instrument system to be the first to dramatically reduce
the cost,
while also increasing the speed, of DNA sequencing. In particular,
Solexa
expects to be the first to deliver whole human genome sequencing at
$100,000
per genome. The company's shares closed at $8.40, up 15%.

Burrill Diagnostics Index (up 3.8%, down 2.1% YTD)
A 90% increase in sales of Cepheid's (CPHD) molecular
diagnostics products
for the first nine months of 2005 as compared to the same period in
2004
helped boost the company's shares in November, which closed at
$10.99, up 73%.
Quidel (QDEL) also performed strongly in November with its
shares closing
the month up 20% at $13.96. With the media focusing on the potential
of a bird
flu pandemic, the company was the beneficiary of investor attention
since it
commands about 48% of the flu-testing market with its Quick Vue
test. This
test detects the presence of the more common influenza A and B
viruses in
patients' nasal swabs. While the diagnostic test isn't specifically
designed
to identify bird flu, some researchers have reported success in
using Quick
Vue to detect the H5N1 strain of the influenza virus.
Although Third Wave Technologies Inc. (TWTI), a leader in
personalized
medicine, received FDA clearance for its Invader UGT1A1
pharmacogenetic test,
designed to detect select polymorphisms associated with adverse
reactions to
Pfizer's chemotherapy drug, Camptosar, the company's shares closed
the month
in negative territory at $2.74, down 24%.

Burrill MID-CAP Biotech Index (up 4%, 5.4% YTD)
Shares of Adolor Corp. (ADLR) surged during the month after
investment
firm Lehman Brothers upgraded the company over recent progress with
its bowel
dysfunction treatment. Adolor has completed enrollment in a Phase
III clinical
trial, comprising approximately 660 patients, designed to evaluate
Entereg(R)
(alvimopan) for the management of postoperative ileus by
acceleration of the
time to recovery of gastrointestinal (GI) function following bowel
resection
surgery. The company's shares closed the month at$14.57, up 38%
Cell Genesys, Inc. (CEGE) sold its manufacturing operation in
San Diego to
Genzyme Corp. (GENZ) for $3.2 million in cash. The operation was
originally
purchased by Cell Genesys from Chiron Corp. in 2001 for $4.8
million. Most of
the approximately 40 employees formerly employed by Cell Genesys
have become
Genzyme employees. Shares of Cell Genesys closed up 9% at $5.85.
It was a roller coaster ride for Pain Therapeutics Inc. (PTIE).
Their
shares tumbled in the month following their announcement that that a
study
showed its painkiller Oxytrex was less addictive than oxycodone, but
the Phase
III clinical trial failed since high dropout rates made the results
not
statistically significant. However, an analyst's upgrade helped stem
the tide
and the company's shares closed at $7.23 up 25%.

Burrill SMALL-CAP Biotech Index (up 4%, down 15.7% YTD)
Palatin Technologies, Inc. (PTN) was one of the top gainers with
its
shares closing up 58% even though financial results for their first
quarter
ending September 30, 2005 revealed a widening net loss. Palatin
attributed
this to increased R&D costs related to PT-141, a drug under
development to
treat male and female sexual dysfunction, and lower license fees from
Mallinckrodt Healthcare related to NeutroSpec, the company's product
for
imaging and diagnosing equivocal appendicitis, which was approved by
the FDA
in July 2004.
However, a reduced loss in Large Scale Biology Corporation's
(LSBC)
quarterly financials and a research license and option agreement
with Growers
Research Group LLC on LSBC's Geneware plant gene expression
technology was not
enough to stop a significant fall in their share value. LSBC closed
at $0.33,
down 40%.
Alnylam Pharmaceuticals, Inc. (ALNY) who is developing novel
therapeutics
based on RNA interference was added to the NASDAQ Biotechnology
Index. Its
shares closed up 31% at $12.56
Shares for Avant Immunotherapeutics Inc. (AVAN) performed well in
November, up 31%, with investors driving up their value following
news that
the company plans to develop a bird flu vaccine. Using in-house
technology
Avant said that it would devote research efforts toward finding a
bird flu
vaccine that can be kept at room temperature.
Cellegy Pharmaceuticals, Inc. (CLGY) is facing delisting from
the Nasdaq
Stock Market since the market value of their common stock had been
below the
minimum price requirements. Cellegy has until December 19, 2005 to
regain
compliance. Its shares closed at $0.63, down 48% in November.

Index 12/31/04 10/31/05 11/30/05 Percent
Percent
Value Value Value
Change Change
For Month
For Year
Burrill Biotech
Select Index 287.54 320.33 340.74 6.37%
18.50%
Burrill
LARGE-CAP
Biotech
Index 368.59 432.70 457.68 5.77%
24.17%
Burrill
MID-CAP
Biotech
Index 162.53 164.69 171.29
4.01% 5.39%
Burrill
SMALL-CAP
Biotech
Index 148.96 120.65 125.57 4.07% -
15.70%
Burrill
Genomics
Index 135.16 114.40 123.96
8.36% -8.29%
Burrill
Biotech
2003/4/5
IPO Index 78.11 68.09 68.69 0.88% -
12.06%
Burrill
Agbio Index 111.02 111.14 114.79
3.29% 3.40%
Burrill
Industrial
Biotech Index 124.23 121.65 124.44
2.30% 0.17%
Burrill
Diagnostics
Index 105.30 99.20 103.00
3.83% -2.18%
Burrill
Nutraceuticals
Index 333.89 408.01 433.19 6.17%
29.74%
Burrill Life
Science
Composite
Index 200.25 223.38 230.91 3.37%
15.31%

Index 12/31/04 10/31/05 11/30/05 Percent
Percent
Value Value Value
Change Change
For Month
For Year
Burrill
Biotech
Select Index 287.54 320.33 340.74 6.37%
18.50%
NASDAQ 2175.44 2120.30 2232.82
5.31% 2.64%
DJIA 10783.01 10440.07 10805.87
3.50% 0.21%
Russell 2000 651.57 646.61 677.29
4.74% 3.95%

SOURCE Burrill & Company
Web Site: www.burrillandco.com

Biotech
Biotech
Entrepreneurs
Arizona
Biotech News
Biotech News

Biotech News 0 comments

Subscribe to biotech-news